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Abstract: A recent explosion in the amount of cardiovascular risk and incipient, undetected 
subclinical cardiovascular pathology has swept across the globe. Nearly 70% of adult Americans 
are overweight or obese; the prevalence of visceral obesity stands at 53% and continues to rise. At 
any one time, 55% of the population is on a weight-loss diet, and almost all fail. Fewer than 15% 
of adults or children exercise sufficiently, and over 60% engage in no vigorous activity. Among 
adults, 11%–13% have diabetes, 34% have hypertension, 36% have prehypertension, 36% have 
prediabetes, 12% have both prediabetes and prehypertension, and 15% of the population with 
either diabetes, hypertension, or dyslipidemia are undiagnosed. About one-third of the adult 
population, and 80% of the obese, have fatty livers. With 34% of children overweight or obese, 
prevalence having doubled in just a few years, type 2 diabetes, hypertension, dyslipidemia, 
and fatty livers in children are at their highest levels ever. Half of adults have at least one 
cardiovascular risk factor. Not even 1% of the population attains ideal cardiovascular health. 
Despite falling coronary death rates for decades, coronary heart disease (CHD) death rates in 
US women 35 to 54 years of age may now be increasing because of the obesity epidemic. Up 
to 65% of patients do not have their conventional risk biomarkers under control. Only 30% of 
high risk patients with CHD achieve aggressive low density lipoprotein (LDL) targets. Of those 
patients with multiple risk factors, fewer than 10% have all of them adequately controlled. Even 
when patients are titrated to evidence-based targets, about 70% of cardiac events remain unad-
dressed. Undertreatment is also common. About two-thirds of high risk primary care patients are 
not taking needed medications for dyslipidemia. Poor patient adherence, typically below 50%, 
adds further difficulty. Hence, after all such fractional reductions are multiplied, only a modest 
portion of total cardiovascular risk burden is actually being eliminated, and the full potential 
of risk reduction remains unrealized. Worldwide the situation is similar, with the prevalence 
of metabolic syndrome approaching 50%. Primordial prevention, resulting from healthful 
lifestyle habits that do not permit the appearance of risk factors, is the preferred method to 
lower cardiovascular risk. Lowering the prevalence of obesity is the most urgent matter, and is 
pleiotropic since it affects blood pressure, lipid profiles, glucose metabolism, inflammation, and 
atherothrombotic disease progression. Physical activity also improves several risk factors, with 
the additional potential to lower heart rate. Given the current obstacles, success of primordial 
prevention remains uncertain. At the same time, the consequences of delay and inaction will 
inevitably be disastrous, and the sense of urgency mounts. Since most CHD events arise in a 
large subpopulation of low- to moderate-risk individuals, identifying a high proportion of those 
who will go on to develop events with accuracy remains unlikely. Without a refinement in risk 
prediction, the current model of targeting high-risk individuals for aggressive therapy may not Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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succeed alone, especially given the rising burden of risk. Estimating cardiovascular risk over a period of 10 years, using scoring systems 
such as Framingham or SCORE, continues to enjoy widespread use and is recommended for all adults. Limitations in the former have 
been of concern, including the under- or over-estimation of risk in specific populations, a relatively short 10-year risk horizon, focus 
on myocardial infarction and CHD death, and exclusion of family history. Classification errors may occur in up to 37% of individuals, 
particularly women and the young. Several different scoring systems are discussed in this review. The use of lifetime risk is an important 
conceptual advance, since $90% of young adults with a low 10-year risk have a lifetime risk of $39%; over half of all American adults 
have a low 10-year risk but a high lifetime risk. At age 50 the absence of traditional risk factors is associated with extremely low lifetime 
risk and significantly greater longevity. Pathological and epidemiological data confirm that atherosclerosis begins in early childhood, and 
advances seamlessly and inexorably throughout life. Risk factors in childhood are similar to those in adults, and track between stages of 
life. When indicated, aggressive treatment should begin at the earliest indication, and be continued for years. For those patients at inter-
mediate risk according to global risk scores, C-reactive protein (CRP), coronary artery calcium (CAC), and carotid intima-media thick-
ness (CIMT) are available for further stratification. Using statins for primary prevention is recommended by guidelines, is prevalent, but 
remains underprescribed. Statin drugs are unrivaled, evidence-based, major weapons to lower cardiovascular risk. Even when low density 
lipoprotein cholesterol (LDL-C) targets are attained, over half of patients continue to have disease progression and clinical events. This 
residual risk is of great concern, and multiple sources of remaining risk exist. Though clinical evidence is incomplete, altering or raising 
the blood high density lipoprotein cholesterol (HDL-C) level continues to be pursued. Of all agents available, rosuvastatin produces the 
greatest reduction in LDL-C, LDL-P, and improvement in apoA-I/apoB, together with a favorable safety profile. Several recent proposals 
and methods to lower cardiovascular risk are reviewed. A combination of approaches, such as the addition of lifetime risk, refinement of 
risk prediction, guideline compliance, novel treatments, improvement in adherence, and primordial prevention, including environmental 
and social intervention, will be necessary to lower the present high risk burden.
Keywords: primary prevention, cardiovascular risk, coronary heart disease, primordial prevention, rosuvastatin, JUPITER study, statin 
drugs, C-reactive protein, inflammation, low-density lipoprotein, high-density lipoprotein, diabetes, metabolic syndrome, Framingham 
risk score, Reynolds risk score, SCORE, coronary artery calcification, carotid intima-media thickness, hypertension, obesity, non-HDL-
cholesterol, LDL-P, dysfunctional HDL, lifetime risk, advanced lipid testing, Bogalusa Heart Study
Introduction: the enormity  
of the challenge
Cardiovascular disease (CVD) claims 2,300 lives each day 
in the United States, averaging one death every 39 seconds. 
In 2006, 81 million people in America suffered with $ one 
type of cardiovascular disease. Presently one in three 
Americans has CVD, and 35% of all American deaths 
are due to the scourge.1 Coronary heart disease (CHD) 
is the leading cause of death in the US and the UK: one 
  coronary event occurs every 25 seconds in America, with 
34% dying within the same year, amounting to one death 
every   minute. On an annual basis, about 785,000 Americans 
have new coronary attacks, and 470,000 have a recurrence, 
with an estimated 195,000 first myocardial infarctions 
that occur silently.1 There were about 406,351 deaths in 
the United States from CHD in 2007, approximately one 
in six of all deaths.2   Thirty-five years ago, the number of 
coronary deaths was significantly higher, and the prognosis 
was limited by the relative dearth of technical, invasive, 
and   pharmacological options.3 Currently, there are about 
6.2   million hospitalizations for cardiovascular disease each 
year in the USA, 730,000 hospitalizations for stroke, and 
7.2 million cardiac and vascular procedures are performed.4 
A similar situation now exists world-wide.5,6
CVD now consumes 17% of the national health budget in 
America, where health expenditures, matching the body mass 
indices (BMIs), are the highest in the world. The cost of CVD 
in the USA has recently grown at an average annual rate of 
6%, and accounts for about 15% of the rise in total medical 
expenditures. During the next 20 years, the prevalence of CVD 
will rise by about 10%, and the costs attributable to CVD will 
triple, simply because of demographic changes in the popula-
tion. By 2030, without any change in prevention or treatment 
practices, it is projected that the number of people with one of 
more forms of heart disease will increase from 36.9% to 40.5%, 
to total 116 million American adults. By then, the incidence of 
heart failure and stroke will have each risen by ≈25%.7
Although the death rate from CHD has fallen, the 
prevalence of risk factors, especially obesity and diabetes, 
continues at an alarming level, actually making the above 
estimates conservative. The present crop of adolescents who 
are overweight will increase the number of obese adults an 
additional 5%–15% by 2035, generating another 100,000 
prevalent cases of CHD. There is increasing evidence that 
obesity is offsetting improvements in CHD mortality,8,9 and 
a recent comprehensive review by the National Research 
Council found that the high prevalence of risk factors, 
particularly obesity, was a major factor accounting for Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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  lagging improvement in longevity in America and developed 
countries.10
Despite remarkable advances considered science fiction 
just a short time ago, treatment success, as cardiologists 
well know, remains a constant uphill struggle. The sobering 
figures above have prompted many epidemiologists and 
preventive cardiologists to suggest that changes in thinking 
and approach in primary prevention have been needed for 
some time. In contrast with the dire predictions outlined 
above, another pathway is possible. A rich data base,11 
including the INTERHEART study12 and recent models,13 
suggest a refreshing, alternative direction. By lowering 
the prevalence of risk factors, there will be an anticipated 
reduction in both CVD events and cardiovascular mortality 
of striking proportions.7
Most risk factors that drive cardiovascular disease 
have genetic, physiologic, behavioral, and environmental 
  components. Nonmodifiable risk factors include age, genetics, 
and gender. Modifiable risk factors comprise smoking, 
dyslipidemia, hypertension, and diabetes, with obesity and 
metabolic syndrome usually included. Emerging, “novel,” or 
nontraditional risk factors for risk assessment include C-reac-
tive protein (CRP), lipoprotein-associated phospholipase A2 
(Lp-PLA2),14 LDL particle number (LDL-P), fibrinogen, lipo-
protein (a) [Lp(a)], small, dense LDL, triglycerides (TG) and 
triglyceride-enriched particles, plasminogen activator inhibitor 
(PAI-1), interleukin-6 (IL-6), and others. Leading contenders 
among imaging techniques capable of refining risk prediction 
or improving management include measurement of carotid 
intima-media thickness (CIMT), coronary artery calcification 
(CAC), and MRI or CT coronary angiography (Table 1).
Risk factors influence the pathobiology of atherosclerosis 
and coronary artery disease in a continuum during a 
complex interaction of genetics and environmental factors 
throughout life. Modifying events along this long time span 
include lifestyle changes, primarily nutrition, exercise, 
stress, comorbidities, pharmaceuticals, particularly statins, 
percutaneous interventions, and surgery.
A significant number of pharmacological agents are 
now prescribed for cardiovascular risk reduction during 
both primary and secondary prevention, as well as during 
treatment of coronary heart disease (CHD). A recent paper 
focused on rosuvastatin, reviewing its properties and some 
details about use in primary prevention.15 This complementary 
paper examines new data, changes in views about primary 
prevention, the rationale for alternative approaches, and 
surveys several recent proposals to improve risk stratification 
and clinical outcomes.
Types of prevention
Prevention, although relatively unfashionable when 
compared to cutting-edge high-tech procedures, addresses 
two of the three goals of medicine: preventing disease, 
relief of suffering, and prolonging life. On the other hand, 
percutaneous coronary intervention (PCI) and coronary 
artery bypass grafting (CABG) excel in relieving suffering 
unresponsive to medical therapy, making the combination 
of prevention and therapeutic procedures a complementary 
union of partners in a continuum of management.
Prevention may refer generally to screening and immuni-
zations to detect, forestall, or limit serious disease. Primary 
prevention denotes delaying or limiting a first event in 
individuals who have not yet been formally diagnosed with 
heart disease. Usage includes individuals with risk factors, 
the latter commonly regarded as if they were in fact diseases 
themselves, since often they are simultaneously causes, 
surrogates, and targets for therapy. Secondary prevention 
seeks to prevent, postpone, or limit recurrence of a clinical 
event in patients who have been previously diagnosed with 
cardiovascular disease. The functional distinction between 
the types of prevention appears to be blurring.16 For complex 
reasons, prevention receives #3% of the health care budget,17 
and prevention measures are underemployed, even in the 
context of a   current ≈55% utilization of all recommended 
effective therapies.18   Cost-ineffectiveness has been   disproved 
for individual primary prevention techniques.19,20 The 
Table 1 Common tools used in cardiovascular risk assessment
Clinical evaluation: history and physical examination
Family history
Global Risk Scoring (FRS, SCORe, Reynolds)
Calculation of lifetime risk
electrocardiogram (eCG)
echocardiography
Stress (exercise) electrocardiography
Myocardial perfusion imaging (MPi)
Stress (exercise) echocardiography
LDL-C (apolipoprotein B, non-HDL-C)
HDL-C
Lipoprotein “little a” (Lp(a))
Lipoprotein fractionation (vAP, NMR)
hsC-reactive protein (CRP)
Lipoprotein-associated phospholipase A2 (Lp-PLA2)
Coronary angiography
Carotid intima-media thickness using ultrasound (CiMT)
Computed tomography for coronary calcium (CAC)
CT coronary angiography
MRi coronary angiography
Abbreviations:  FRS,  Framingham  Risk  Score;  LDL-C,  low  density  lipoprotein 
cholesterol;  HDL-C,  high  density  lipoprotein  cholesterol;  CT,  computerized 
tomography; MRi, magnetic resonance imaging.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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National Institute for Health and Clinical Excellence (NICE) 
in the UK estimated that a 1% population-wide lowering of 
cardiac risk factors would net substantial savings,21 yet even 
with widespread agreement, prevention services remain low 
on US payers’ priorities, and are similarly undervalued by 
the public.
Primordial prevention
Primordial prevention, a term first used by Strasser,22 refers 
to individual behavioral lifestyle characteristics that achieve 
a level of health that does not permit risk factors to appear. 
The American Heart Association (AHA) incorporated the 
powerful principle of primordial prevention in defining 
“ideal cardiovascular health” as a goal in reducing cardiac 
and stroke mortality 20% by year 2020.2 Ideal cardiovascular 
health consists of the absence of cardiovascular disease, a 
healthy lifestyle (sufficient exercise, a superior diet score, 
absence of smoking, and BMI , 25 kg/m2), and ideal 
health factors (untreated normal values of blood pressure, 
cholesterol, and fasting glucose). These parameters, termed 
Life’s Simple 7TM, are presented in an AHA educational site, 
mylifecheck.org, which promotes primordial prevention 
(Table 2). Presentation of material is layered, clear, in 
language that is easily understood, and user-friendly. The 
AHA Goals also emphasized the need for a plant-based diet 
containing legumes, nuts, seeds, and minimum amounts of 
trans and saturated fats.2
Reversal of existing risk factors does not equal the 
degree of protection afforded by primordial prevention.23,24 
Since atherosclerosis begins at an early age and progresses 
throughout life, primordial prevention is uniquely successful 
in combating CHD, but also adds protection against other 
degenerative diseases to reduce all-cause mortality. Dietary 
changes alone can produce – and completely reverse – lesions 
of CHD in primates25 and intensive lifestyle programs may 
cause lesion regression in humans.26 Individuals who achieve 
primordial prevention are uncommon, with fewer than 5% 
achieving ideal cardiovascular health as they approach 
middle life.2 When individuals do enter middle age without 
risk factors, their cardiovascular protection is extraordinary 
and they enjoy an additional 10 years of life.27,28 A number 
of recent impressive prospective studies and models support 
these findings, suggesting that population-based primordial 
prevention is capable of reducing CHD deaths to approxi-
mately 10% of the current expected rate.8,11
Among the strategies to lower risk are proposals involving 
reeducation, reorientation, and motivation of individuals so 
their lifestyles do not permit risk factors to develop, or slow 
to the extent that their lifetime risk is lowered. Weight loss of 
15% or more of body weight with other dietary and lifestyle 
interventions, especially exercise, will drastically reduce 
cardiovascular risk up to 45% and simultaneously lower 
CRP levels.29 School- and community-based initiatives, 
improvement in diet and food quality, social support, 
and other incentives are among the approaches available. 
Health, nutrition, and exercise illiteracy are prevalent, with 
misinformation and unrealistic expectations also common. 
From an intuitive and qualitative view, therefore, corrective 
education would appear beneficial. Overall, however, such 
current methods to positively influence individual behavior 
have been unsuccessful. A recent Cochrane review of 55 trials 
reported that counseling and educational programs can lower 
risk factor burdens modestly, but do not lower CHD events, 
total or CHD mortality in the general population, and are 
therefore not recommended or evidence-based.30 They did 
find, however, that patient education and counseling may 
be useful in high-risk diabetic or hypertensive populations, 
from which the inference was made that patients with 
pre-existing disease benefited, but not those who were 
undiagnosed. Removal of education, behavioral intervention 
and counseling, as suggested, would leave policy decisions, 
largely environmental, as the remaining technique available 
for primordial prevention.
This report30 uniquely disagrees with a large body of 
evidence that preceeded it, and is at odds with pathological 
data and available guidelines concerning cardiovascular risk 
management.2,6,31,32 It suggests that current initiatives, such 
as the American Heart Association’s Life’s Simple 7TM, will 
Table 2 Ideal Cardiovascular Health, defined by the American 
Heart Association, now known as “Life’s Simple 7TM”, is composed 
of four behaviors and three factors2,*
1. Not smoking or quitting over 1 year ago.
2. A body mass index ,25 kg/m2.
3.   exercising at a moderate intensity $150 minutes (or 75 minutes  
at vigorous intensity) each week.
4.   Eating a “healthy diet”: adhering to four to five important dietary 
components
  • sodium intake ,1.5 g/day; 
  • sugar-sweetened beverage intake ,36 oz weekly; 
  • $4.5 cups of fruits and vegetables/day; 
  • $three 1 oz servings of fiber-rich whole grains/day; 
  • $two 3.5 oz servings of oily fish/week.
5. Maintaining total cholesterol (TC) ,200 mg/dL.
6. Keeping blood pressure ,120/80 mmHg.
7. Keeping fasting blood glucose ,100 mg/dL.
Notes: *Other recommendations include $ four servings of nuts, legumes and 
seeds/week; # less servings of processed meats/week; less than 7% total energy 
intake as saturated fat.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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have limited effect, and that public health policies to lower 
cardiovascular risk in most countries may be misguided. 
Ignoring patient education, as is implied, is also contrary to 
the Institute of Medicine’s goal of a patient-centered health 
system33 and simultaneously undermines a core constituent 
of models to improve care and patient value by allowing 
participation in clinical decision-making.34 The components 
of patient attitudes and behavior are complex, and are of 
such crucial importance that further analyses, such as done 
by White,35 are needed to refine future approaches.
The accompanying editorial36 observed that there were 
no recent large-scale randomized controlled trials on the 
issue, and reviewed the pitfalls and perils involved in making 
educational and behavioral modification programs effective. 
The design, recruitment, administration (especially adherence 
verification), and successful completion of such a study 
presents enormous challenges. Funding for such a project is 
highly unlikely. In the absence of such randomized trials, the 
editorialist stressed reducing dietary salt intake, legislating 
for smoke-free public spaces, and exercise parks to facilitate 
primordial prevention. Unfortunately, these policies too 
have encountered obstacles. Environmental restructuring to 
improve health has been challenged legally, and has been 
considered intrusive in some venues.
Shortly thereafter, the Global Burden of Metabolic Risk 
Factors of Chronic Diseases Collaborating Group published 
three reports that described global population-level changes 
in body-mass index (BMI), systolic blood pressure, and total 
cholesterol over three decades.37–39 Involving 3.0–9.1 million 
participants over 321–960 country-years, their three studies 
found that obesity rates doubled between 1980 and 2008, 
overweight affected one in three adults, and obesity affected 
one in nine adults in the world. Global BMI increased on 
average 0.4 to 0.5 kilograms, about 0.9 to 1.1 pounds, per 
decade for men and women. Changes in blood pressure and 
cholesterol varied according to income and location, and 
sometimes were disparate with the rises in BMIs. Even so, 
the high cardiovascular disease burden in low- and middle-
income countries over the next few decades was deemed 
dismal and an emergency.40 The solution proposed to avert 
tens of millions of preventable deaths was, not surprisingly, 
population-based risk control.
High-risk individual model  
vs a population-based model
The current paradigm in both primary and secondary 
prevention seeks to identify individuals at high risk for 
cardiovascular events through screens and target them for 
additional evaluation, stratification, and intensive treatment. 
Guidelines concentrate on maximizing use of these steps to 
produce the greatest reduction in clinical events, quality of 
life, and survival. Throughout the past four decades, this 
approach has been rewarding, with extraordinary advances 
that have been reflected in large decreases in cardiovascular 
mortality. For example, for every 10% rise in treatments of 
LDL-C elevations in the population younger than 80 years, 
approximately 8,000 deaths could be prevented annually,20 
and for a 10% rise in hypertension therapy, about 14,000 
deaths per annum would be averted. A fall in risk factors 
within the population accounts for about half of the lowering 
of death rates during the past 40 years.41–45 Despite this 
improvement, death from coronary heart disease remains at 
the top of the list, and will also be the leading cause of death 
world-wide within the decade. Moreover, the recent lowering 
of CHD deaths has shown signs of slowing, probably due to 
the dual epidemics of obesity and diabetes. From a public 
health perspective, somewhat over 40% of CHD events occur 
in the 6% of the population with manifest disease, much of 
which is preventable with effective measures.46
Geoffrey Rose47–50 a British epidemiologist, compared 
health consequences when individual care is given to high-
risk individuals, often those who make poor lifestyle choices, 
compared to treating the entire population. He also addressed 
environmental and behavior characteristics of the population 
in general. Following a population-based strategy to control 
risk, changes in a large number of people resulted in a smaller 
individual benefit, and required a relatively larger political 
and economic change for success.47 Cultural and regional 
differences, ie, “diversity”, complicated implementation. 
Rose said “mass diseases and mass exposures require mass 
remedies”, emphasizing that sick individuals arise from sick 
populations, and that the number of persons with undesirable 
levels of risk factors depends upon the average risk in the 
population.49 He observed that the behaviors of many subjects 
with low risk have a greater impact upon disease prevalence 
than fewer individuals with high risk.48 Treatment of high-risk 
individuals tended to be crisis intervention and only pallia-
tive, whereas population intervention targeted fundamental 
causes.
Less than 10% of the population is at high risk for 
cardiovascular disease, but the low to intermediate risk 
group is so large that most cardiovascular events will actu-
ally arise from that population.1,47,51 As a result, 90% or 
more of cardiovascular events will occur in individuals 
with one or more risk factor, somewhat under half of the 
population.52 Importantly, this subpopulation with cardiac Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
330
Kones
events would not qualify for intensive diagnosis or treatment 
using high-risk filters. Lowering the risk factor burden in 
the general population through lifestyle, environmental, 
and social changes would be expected to produce greater 
reductions in CHD risk.
High burden of cardiovascular risk
Past and future trends are unfavorable
During the last two decades, adherence to a healthy   lifestyle 
has deteriorated significantly.11,53,54 From 1988–2006, 
the prevalence of obesity increased from 28% to 36%, 
consumption of $5 portions of vegetables or fruits was nearly 
halved, level of physical activity also fell, while alcohol 
consumption rose. Patients with diabetes or heart disease 
also reported poor performance in these categories.
Examining 10-year trends in chronic illnesses, Paez 
and collaborators55 used the prevalence of self-reported 
conditions during expenditure surveys, and noted that in 
2005, 44% of Americans had at least one chronic disease. 
The number of persons with three chronic conditions rose 
sharply, however, when compared with the number with 
one illness. For persons ages 45–64 years, the prevalence of 
multiple chronic conditions in 1996 was 13%, and by 2005 
rose to 22%. In 2010, an analysis by Health and Human 
Services reported 27% of the population suffered with 
multiple chronic illnesses.55
Today very few Americans are at low risk for heart 
disease. Continuing reports of rising prevalence of 
overweight and obesity not only reflect acceleration, but 
absolute levels are higher than ever before.56,57 Since the data 
are self-reported, the actual numbers are likely worse. Even 
in the face of consistently rising risk, 65% of Americans rate 
their health as good, but overweight and obesity alone exceed 
this number. Over 55% of young adults have at least one 
CVD risk factor, and over 37% reported having $ two risk 
factors for CVD (with only 35% under control), all reflecting 
a dissociation between perception and reality. Indeed, the US 
Centers for Disease Control and Prevention (CDC) reports 
that Americans are now sicker than ever.58 In Canada too, 
90% of citizens report they are healthy, when actually 90% 
of them have $ one risk factor, also an apparent denial of 
the prevalence of risk factors.59
According to American Heart Association criteria, 
perhaps 5% of Americans were considered to have ideal 
cardiovascular health when the 2010 Impact Goals were 
presented,2 but subsequent evaluation reveals it is actually 
less than 1%. If recent increases in the incidence of diabetes 
continue, the prevalence of diabetes in American adults, 
including undiagnosed cases, is projected to rise from the 
present 14% to 33% of American adults by 2050.60 Even 
with vigorous intervention, a significant increase in diabetes 
prevalence will be inevitable.61 Clyde Yancy MD, Chief of 
Cardiology at Northwestern University and past president of 
the AHA, in an editorial about the challenges of lowering risk 
in the population, recently termed the cardiovascular health 
status in America “miserable”.62 Unfortunately, an end to 
the dual epidemics of obesity and diabetes is not in sight.63 
Although excellent information is available,64,65 there is no 
comprehensive, population-wide plan being implemented 
with any evidenced-based hope of reversing the rise in 
prevalence for either condition.58,63
Prevalence of risk factors is high
The current cardiovascular risk burden is oppressively high. 
According to recent NHANES data, about half of American 
adults have one or more of the three major risk factors: 
dyslipidemia, hypertension, or diabetes.53 Approximately 
13% have two of these risk factors, and about 3% have 
all three. The National Center for Health Statistics also 
estimates that 15% of adults have one of more of the three 
risk factors but remain undiagnosed and hence untreated. 
The 2010 Update on Heart Disease and Stroke Statistics1 
reported the following prevalence rates from various sources: 
34% hypertension, 33% obesity, 32% pediatric obesity or 
overweight, 29% prediabetes, 8% undiagnosed diabetes, 
34% metabolic syndrome, 21.2% tobacco use, and 59% 
abstaining from any vigorous activity. Other reports, a short 
interval later, indicate a higher incidence of hypertension, 
36% prediabetes, and 27% undiagnosed diabetes, and 
11.2% of adults with both prehypertension and prediabetes.2 
In 2009, the diabetes population was predicted to double or 
triple within 25 years.60 During the same period, a review of 
surveys estimated that among Americans $30 years, 13.7% 
of men and 11.9% of women had diagnosed diabetes, and 
about one-third of them had not yet been diagnosed. The most 
recent data from the CDC66 amended these figures, reporting 
a rise in prevalence of prediabetes to 35% in adults older than 
20 years, to 50% in those over 65 years of age. The strain 
on the healthcare system resulting from both obesity67 and 
diabetes is remarkably high.60,68 Since the surveys incorporate 
older information, self-reporting, and imperfect criteria in 
some instances, actual prevalences may be higher for all risk 
factors. For instance, the quoted 34% prevalence of metabolic 
syndrome is based upon NHANES 2003–2006 figures, and 
is now significantly higher in the USA, reaching 53% in 
some subpopulations. Hence in the 2011 Update on Heart Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Disease and Stroke Statistics,69 the members of the writing 
group noted that “prevalence and control of traditional risk 
factors remains an issue …” The prevalence of obesity may 
be rising ≈1.4% every 2 years in America, with the current 
prevalence of visceral obesity at ≈53%.70
The magnitude of the burden of risk factors may in fact 
be underestimated. Recently 1,933 middle-aged subjects 
in the community-based Heart Strategies Concentrating on 
Risk Evaluation (Heart SCORE) study were evaluated for 
the seven characteristics – behaviors and factors – of ideal 
cardiovascular health as defined by the AHA.71 Only one 
participant (0.1%) met all of them, and fewer than 10% 
of met $ five components of ideal cardiovascular health. 
Thirty-nine subjects (2.0%) had all four components of ideal 
health behaviors, while 27 (1.4%) had all three components 
of ideal health factors (Table 1). About 81% of their cohort 
was overweight or obese, possibly due to a high proportion 
of blacks (44%), and low prevalence of cardiovascular health 
was noted in all subgroups: ethnicity, gender, education, 
and income. Blacks had 82% lower odds of having $ five 
components of ideal cardiovascular health (odds ratio 0.18, 
95% confidence interval [CI]: 0.10 to 0.34; P , 0.001). 
These numbers offer a telling summary, and suggest that 
when risk factors are carefully evaluated, a truer, even more 
gruesome index of the present risk burden emerges. Indeed, 
in this study one limitation was the possibility that the level 
of cardiovascular risk in the general population might even 
be higher, because volunteer participants had a relatively low 
prevalence of tobacco use and a high educational level.
Epidemiologists identify three phenomena now accel-
erating cardiovascular risk: obesity, diabetes, and the 
  progressive aging of the population.72–76 The first two, obesity 
and diabetes, including metabolic syndrome, respond to 
primordial, primary, and secondary prevention. The third, 
a higher proportion of the elderly within the population, is 
of course, untreatable. Reversal of traditional risk factors 
in elders is, however, beneficial and presents therapeutic 
opportunities.
The level of cardiovascular risk in children and young 
adults is also of major concern,77,78 with one-third of this 
population overweight or obese. As a result of an epidemic 
of childhood obesity and the rising appearance of diabetes 
type 2 in the pediatric age group, the number of risk   factors 
now found in children is alarming. Physical activity is 
below recommended levels in 17% of adolescents, and 20% 
of this population has at least one abnormal lipid value.79 
Cardiovascular risk, even in the pediatric age group, forms 
a continuum that has been carefully tracked over the human 
lifetime, with dominant and close associations between risk 
factors, CHD risk, and poor outcomes along the way.80,81
Screening and control of  
cardiovascular risk
Despite the high burden of cardiovascular risk, screening 
receives a disproportionately small amount of attention and 
support. Given the comparative death rates and numbers 
succumbing to cardiovascular disease (CVD), cancer, and 
HIV , the screening frequencies and filters for asymptomatic 
CVD (BP, ambulatory monitoring, lipid profiles, advanced 
lipid testing, others) are much less favorable than for   cancer 
(with less than 10% of the funding, based upon breast 
  examinations and colorectal screening data) and HIV than for 
asymptomatic CVD.82 In addition, support and enthusiasm for 
primary prevention, eg, an initial myocardial infarction (MI), 
is woefully behind that for secondary prevention (recurrent 
MIs), although the benefits may be greater over an enlarged 
population base and longer horizon for the former.
In addition, there is ongoing concern that control of risk 
factors, although progressively improving, still remains 
far from evidence-based targets.11 A review of NHANES 
data from 2005 to 2008 recently quoted a prevalence of 
hypertension in American of ≈31%, about 70% receiving 
treatment and a control rate of 46%.83 An accompanying 
report, also from the CDC for the same period,84 estimated 
33.5% of adults had elevations in LDL-C, only 48% received 
treatment, and 33.2% were controlled. Overall, well over 
half of the population with risk factors does not have them 
under control, and #10% with multiple risk factors have 
them within target ranges.
Poor adherence is itself a major “risk factor” of substantial 
complexity and underrated significance.85–88 About one-
quarter of all new prescriptions are not filled,89 and fewer 
than half of patients may eventually be taking the drug 
prescribed.90–92 Therefore, when one discounts the patients 
who are undiagnosed, undertreated, considers adherence 
shortfalls, and significant residual risk, discussed further 
below, it becomes evident that current prevention effectively 
reduces a far smaller portion of total cardiovascular risk than 
is customarily believed.
Global risk burden is high
High burdens of cardiovascular risk exist world-wide, 
as reported by the Institute of Medicine,5 World Heart 
Federation, and in the EuroAspire studies.93 Pediatric 
obesity has also become a global menace.94 Similarly, the 
worldwide prevalence of diabetes is an imposing problem, Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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with a staggering 69% rise in numbers of affected adults 
in   developing nations anticipated by 2030, over three 
times greater than in developed countries,95 which will tax 
health care systems everywhere.96 All told, while   effective 
prevention of diabetes is well-documented, new data   creates 
uncertainty, implementation is fragmented, and some 
initiatives remain in conceptual suspension globally.97
In the 2011 Heart and Stroke Foundation Report on 
Canadians’ Health, risk burden was considered high. The 
perceptions of self-reported behaviors were compared to 
the best estimate of actual prevalence of five general risk 
factors. They concluded that in four categories Canadians 
were in denial about their health behaviors.59 As noted 
elsewhere, self-reporting of health habits is often inaccurate 
because positive behaviors are overreported, and negative 
habits are underreported. In this instance even as reported, 
a disparity between perception and actual frequencies were 
identified (Table 3). A similar table based upon NHANES 
or EuroAspire data would show even greater discordance in 
the USA and EU. Of concern are the numbers of patients 
not asked about their use of tobacco or family history for 
heart disease, and in whom no weight or blood pressures 
were recorded by practitioners during visits. In an effort to 
improve cardiovascular risk factors, a web-based e-tool is 
available as a smart phone application, My Heart&Stroke 
Health App™, is downloadable from www.heartandstroke.
ca/mobileapps, or the interactive evaluation is also offered 
at www.heartandstroke.ca/risk. The reader will notice the 
similarity to the American Heart Association’s Life’s Simple 
7TM, indicating an endorsement by the HSF of the power and 
necessity of primordial prevention.
Risk burden in developing nations
All of the above generally applies to poorer developing 
nations, which have been included in the epidemic of 
chronic disease that sweeps across the world. Traditionally 
noncommunicable disease (NCD) deaths have been 
overshadowed by those from communicable diseases (CD), 
and therefore NCDs have not been included in development 
goals in such countries.98 There is no nation in which the 
prevalence of cardiovascular disease will not rise in the next 
decade; only in sub-Saharan Africa does the prevalence of 
CD exceed or equal that of NCD. NCD accounts for about 
60% of all deaths globally, and cardiovascular disease is a 
major cause. The relative rise in world-wide incidence of 
CVD is basically due to lower fetal and neonatal mortal-
ity, greater use of tobacco, and increased urbanization, 
with attendant rises in fat and energy consumption, lower 
physical activity levels, and, according to INTERHEART 
data, greater psychological stress.99 Currently, emphasizing 
CD prevention rather than NCD only widens disparities in 
cardiovascular care to the poor, who have a high risk bur-
den that leaves them vulnerable.100 Thus far, conventional 
ideas concerning risk factors and subsequent development 
of cardiovascular disease appear to apply to developing 
nations, but it is unclear whether techniques and goals are 
relevant. Especially with considerable doubt about how best 
to control risk factors in a familiar and stable environment, 
whether we are in fact exporting inapplicable intensive 
“solutions” for different cultures is currently being debated. 
In other countries, such as China, it is anticipated that the 
principles successfully employed in Western nations will 
also be productive.
Franco et al101 also call attention to the global   emergency 
faced by countries of low- and middle-income, given the high 
burden of cardiovascular risk, the dire need for   primordial 
prevention, and the multiple potential sources of resistance 
that impede implementation. The NCD Alliance, with 
The World Heart Federation as a component of The NCD 
  Alliance, is aggressively urging implementation of the 
WHO 2008–2013 Action Plan for the Global Strategy for 
the Prevention and Control of NCDs, as well as the Global 
Strategy on Diet, Physical Activity and Health, which set 
forth strategies for primordial prevention.
Table 3 Cardiovascular risk factors as reported in the 2011 Heart and Stroke Foundation Report38
Risk factor Self-reported  
perception  
(% participation)
Actual  
prevalence  
(%, estimated)
Not assessed by  
health care provider (%)
Impact upon 
life expectancy   
(years)
Smoking 23 20 37 -13.9
Obesity  
(age 18 or over)
18 24 weight: 40%  
waist measure: 67%
-4.0
Physically inactive in leisure time 31 48 44 -3.6
High blood pressure 17 19 18 -2.4
vegetable and fruit intake ,5+/day 39 54 52 -1.3
Data from the Heart and Stroke Foundation (HSF) poll of 2000 Canadians performed in December 2010, self-reported from the 2009 Canadian Community Health Survey, 
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Primary prevention of coronary heart disease
Coronary heart disease begins 
in childhood and progresses 
throughout life
Primordial, primary, and secondary prevention are under-
pinned by convincing evidence that atherosclerosis begins 
in infancy,102 has an incubation period of decades, and 
progresses throughout an individual’s lifetime. At the same 
time, evidence is also accumulating that risk factors, such 
as obesity, have prenatal beginnings.69
The pathology of early stages of atherosclerosis in chil-
dren and adolescents is a function of the same traditional risk 
factors that affect adults. Worsening of risk factors acceler-
ates the disease, but their improvement slows or is even 
capable of reversing the process. The longer the exposure to, 
and the greater the intensity of, the risk factors involved, the 
higher the atherosclerotic burden will become.103,104
Epidemiological, pathological,105,106 and risk factor 
data79,107,108 confirm that the atherogenic process already incu-
bates during childhood, and can even be detected in utero.109 
Fatty streaks, a common early manifestation of atherosclero-
sis and well-developed in many young adults, are present in 
37% of asymptomatic, otherwise healthy organ donors from 
ages 20–29.110 These findings are consistent with reports of 
significant coronary atherosclerosis in the majority of young 
soldiers who died on the battlefield.111,112
The Bogalusa Heart Study (BHS), directed by Dr Gerald 
S Berenson for the past 39 years, has clearly established the 
significance risk factors have in youth, now well described 
in about 1000 publications and four books.78,80,113–117 
Observations from the BHS show that the major etiologies 
of adult heart disease and atherosclerosis: hypertension, 
dyslipidemia, and obesity, begin in childhood, with ana-
tomic changes evident by 5–8 years of age. Autopsy studies 
demonstrate lesions that correlate with risk factors116 One 
of the most striking of the findings in the Bogalusa study, in 
addition to the early presence or progression of childhood 
risk factors, was their tracking into adulthood.118 A recent 
contribution is a retrospective cohort study of adults 19–39 
years of age who were followed for an average of 17 years 
since childhood.115 Adverse levels of glucose homeostasis 
variables in childhood persisted into adulthood but also 
predicted adult pre-diabetes and diabetes, and correlated 
with cardiometabolic risk factors. In this regard, a significant 
relationship between excess visceral fat, dyslipidemia, 
hypertension, and elevations in CRP levels has also been 
established in children and adolescents.119–121
Magnussen et al122 studied changes in adiposity (BMI, 
waist circumference, skinfold thickness), fitness (bicycle 
testing), plasma lipids (TC, LDL-C, HDL-C, TG),   smoking 
and socioeconomic status (parental education level) in 539 
young Australians in the Childhood Determinants of Adult 
Health Study. Baseline measurements were made in 1985 when 
participants were 9, 12, and 15 years old, and again between 
2004 and 2006. Among those with hypertriglyceridemia in 
youth, 79% of males and 97% of females had normal values 
∼20 years later. The majority of those with elevated levels of 
HDL-C at follow-up had normal levels at baseline. Both TC 
and LDL-C tended to be more constant, and most youngsters 
with elevations at baseline had them at follow-up, later in life. 
When participants had adverse lipid profiles at baseline, if 
they also gained weight, or continued to smoke during the 
interval, at follow-up they were more likely to have dyslipi-
demia as well. Similarly, those without adverse lipid profiles 
at baseline were significantly more likely to have dyslipidemia 
later if they gained weight or continued to smoke in the 
interim. Last, those who had normal lipid profiles at baseline, 
but who developed higher risk at follow-up had greater gains 
in weight, reduced fitness, and failed to rise socioeconomi-
cally. Also of note was the association of long-term aerobic 
exercise training and upward social mobility from youth to 
adulthood, with higher HDL-C levels. The data suggested 
that, whether dyslipidemia was present or not in youth, risk 
factor modification significantly impacted risk when those 
individuals became adults some 20 years later.
The Pathobiological Determinants of Atherosclerosis 
in Youth (PDAY) studied 2,876 persons 15–34 years of age 
who died of external causes, and found a strong concordance 
between coronary and aortic atherosclerosis and risk 
factors.123–126 The early PDAY score of modifiable risk factors 
and its variation predict risk in youth and may be useful in 
identifying high risk individuals.
Recent imaging studies reflect the same pathophysiology. 
In the Coronary Artery Risk Development in Young Adults 
(CARDIA) study81 of 3,258 individuals ages 18–30, the 87% 
with nonoptimal lipids were about 5.5-fold more likely to have 
coronary artery calcium deposits 20 years later,   compared 
with participants with the lowest lipid values.   Coronary cal-
cium prevalence was 8% in young adults with optimal LDL-C 
levels (,70 mg/dL, or ,1.81 mmol/L), but 44% in those with 
LDL-C cholesterol levels of $4.14 mmol/L ($160 mg/dL). 
HDL cholesterol was also predictive. Hence, the CARDIA 
trial demonstrated that nonoptimal levels of LDL-C and 
HDL-C during young adulthood are independently associated 
with CHD 2 decades later.
The Cardiovascular Risk in Young Finns study127 
sought to determine whether childhood risk factors were Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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associated with a 6-year change in carotid intima-media 
thickness (CIMT) in young adulthood independent of the 
current risk factors. In 1,809 subjects who were followed 
for 27 years from baseline (in 1980, age 3–18 years), 
CIMT was measured both in 2001 and 2007. Childhood 
risk factors assessed included LDL-C, HDL-C, BP, obe-
sity, diabetes,   smoking, physical activity, and frequency 
of fruit consumption. In participants with zero, one, two, 
and $ three risk factors, CIMT increased during 6 years 
by 35, 46, 49, and 61 µm (P = 0.0001). This relationship 
remained significant after adjustment for adulthood risk. 
Of the individual childhood variables, physical inactivity 
and infrequent fruit consumption were associated with 
accelerated CIMT progression after adjusting for the adult 
risk factors. The associations of childhood lipid values 
and BMI with CIMT progression became nonsignificant 
when adjusted for current (adulthood) risk factor levels. A 
composite childhood risk factor score was also associated 
with CIMT progression and this score remained significant 
in adulthood after adjustment. In those risk factors with 
greater relative importance of adult   values – HDL/LDL 
ratio and obesity – correction of adverse childhood factors 
in adulthood appeared to attenuate the ill effects of child-
hood burdens. The data therefore suggest that interventions 
to improve lipid and weight abnormalities between youth 
and adulthood would be productive.
Data from The Cardiovascular Risk in Young Finns 
Study, the Childhood Determinants of Adult Health Study, 
the Bogalusa Heart Study, and the Muscatine Study for 
the International Childhood Cardiovascular Cohort (I3C) 
Consortium were combined in order to investigate the age at 
which risk factors influenced CIMT later in adulthood.128 All 
together, 4,380 participants had TC, BP, BMI, TG measured 
from age 3–18 years, and CIMT was performed in adulthood, 
ages 20–45 years, mean follow-up 22.4 years. The number 
of childhood risk factors was predictive of higher CIMT 
when measured at ages 9, 12, 15, and 18 years, whereas 
associations with risk factors measured at 3 and 6 years were 
not significant. The greater the number of risk factors, the 
higher was the probability of a raised CIMT. A 9-year-old 
obese child with two additional risk factors would have 
double the risk of a CIMT in the top decile of the adult 
distribution, as compared with a child without cardiovascular 
risk factors.129 The accompanying editorial noted that i) these 
data underscore the need to begin population-wide risk 
reduction in early youth, which is applicable to whites and 
blacks world-wide; ii) screening is meaningful from age 
9 years onward; iii) current data indicate the absence of risk 
factors in children is associated with a low likelihood of 
atherosclerosis; iv) screening for dyslipidemia, BP, and BMI 
in children is supported; but v) how to select those children 
for aggressive risk reduction remains unknown. Details about 
treatment of pediatric dyslipidemia are discussed in recent 
reviews.130–137
These studies are consistent with a model in which 
atherosclerotic lesions, initially in the form of fatty streaks, 
advance seamlessly over decades to more mature, fibrous 
plaques found later in life. The disease progresses, at different 
locations with variable rates, through adulthood110–114,123,138,139 
Intracoronary ultrasound studies in donor hearts demonstrates 
coronary artery plaques $0.5 mm in 17% of hearts in 
13–19 year olds, which rises to 60% in 30–39 year olds.110 
The speed of progression depends not only upon the time of 
appearance of the risk factor, but also strongly depends upon 
the number of risk factors present. By the time lesions are 
identified, or symptoms appear, the disease is diffuse, eleva-
tions in systemic biomarkers may be present, and pathology 
has been in progress for years. Although a significant portion 
of the total duration of the disease precedes the diagnosis, the 
accelerated rise in risk – and events – may be skewed toward 
later years. This long asymptomatic period, traditionally 
ignored, needs greater attention and simultaneously provides 
untapped opportunity.
Since lifestyles and behaviors affecting cardiovascular 
risk are learned early in life, health education should be 
emphasized at that time.78 Epidemiologists, preventive 
and pediatric cardiologists, and pathologists all agree that 
up to 90% of heart disease can effectively be prevented, 
and promotion of healthy lifestyles, nutrition and adequate 
exercise should begin in childhood. Moreover, while risk 
factors are already significant in young adults (59%) and 
LDL-C elevations are not uncommon, screening remains 
inadequate.140 Among 20,266 fifth-grade children from 
the Coronary Artery Risk Detection in Appalachian 
Communities (CARDIAC) Project (796), 71.4% of 
children met the National Cholesterol Education Program 
(NCEP) guidelines for cholesterol screening on the basis 
of positive family history. Of those, 8.3% had an LDL-C 
$130 mg/dL; 1.2% of them were eligible for treatment with 
an LDL-C $160 mg/dL. Of the 28.6% who did not have a 
positive family history, ie, did not meet NCEP guidelines, 
9.5% had an LDL-C $130 mg/dL, and 1.7% with LDL-C 
$160 mg/dL warranted treatment. Therefore, many children 
with dyslipidemia are being overlooked, since family history 
is not an effective indicator for screening. Weight was not a 
variable in the study.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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While the composition of the “ideal diet” for cardiovascular 
protection continues to be debated,63 it is not the uncertainty 
of dietary efficacy upon lipid levels to lower risk, nor lack of 
knowledge about other risk factors upon cardiovascular 
outcomes, but rather ineffective implementation that impedes 
meaningful progress. Unfortunately, individual-, school-, and 
community-based programs thus far have had mixed results 
for a number of reasons.125,141 The rise in pediatric obesity 
is of concern to pediatricians.142–144 and endocrinologists.145 
Despite the evidence linking early presence of risk factors and 
adult risk, confirmatory data from other studies, and recent 
emphasis on primordial prevention, relative inaction on the 
part of public health authorities continues.117 Dr Berenson, 
with a half-century of experience, aptly summarizes the 
present status of preventive cardiology as a “hard sell”, 
despite overwhelming acceptance and vocal support.
Global cardiovascular risk scoring  
for stratification
For primary prevention patients, guidelines recommend, 
and many physicians use, the classic Framingham Risk 
Score (FRS) to objectively estimate the absolute risk of 
a   coronary event (CHD) during a period of 10 years146–149 
Inputs of age, gender, total cholesterol, tobacco use, HDL-C, 
TC, systolic blood pressure, and treatment status are entered 
into multivariable equations. The combination of risk factors 
generates a risk estimate for fatal and non-fatal CHD events, 
and subjects are classified into high-risk ($20% risk), inter-
mediate-risk (10%–20%), and low-risk (,10%) categories. 
A number of global risk score   alternatives to FRS exist based 
upon different cohorts – SCORE,150 QRISK151 ASSIGN,152 
the 2001 ATP-III Risk Estimator (FRS-based)153,154 
and PROCAM155 – as well as the Reynolds Risk Score 
incorporating CRP for women156 and for men157 (Table 4). 
Risk scoring is a considerable improvement over personal 
physician judgment, and has been used for stratification 
and to guide evidence-based treatment.158–161 Each scoring 
system is most accurate when applied in the population used 
for its development. Calibration – the extent of agreement 
between what is observed and predicted – depends upon 
prevalence of risk factors and coronary event rates in given 
populations. For American Indians and Americans of Asian-, 
Chinese- and Hispanic-descent, the FRS overestimates risk, 
which may be corrected with recalibration. FRS scores are 
clinically validated,154 globally accepted, and have withstood 
the test of time. Dent162 suggested that the prevalence of 
CHD in Framingham has been reduced by improvement 
in risk factors, particularly smoking, and this change in 
population characteristics accounts for inaccuracies when 
using FRS tools. He also believes that since the original 
cohort was Caucasian and socioeconomically advantaged, 
the FRS may be limited when applied to ethnically diverse 
groups.162 In a variety of populations in North America, 
average FRS 10-year predictability of CHD is approximately 
65%–70%.154 The FRS does not include a family history 
of premature cardiac events, an independent and powerful 
risk factor for CHD.163–168 To enhance features and utility, 
another version of the FRS was developed to predict 10-year 
global cardiovascular risk and specific events of CVD: 
coronary, cerebrovascular, and peripheral arterial disease 
and heart failure.169 Unfortunately, there is suboptimal use 
of scoring systems providing estimates of absolute 10-year 
risk, with only 17%–47% of practitioners performing such 
assessments.170–173 An informal survey suggests actual use 
among cardiologists and internists may even be lower.174 
A recent preliminary report from the PARADIGM registry 
indicated that as many as 65.7% of high-risk patients in 
Canada were being misclassified, with about 34% of primary-
care physicians using the FRS, 28.5% relying upon clinical 
judgment, while others are misapplying CRP recommenda-
tions based upon JUPITER findings.175
While the FRS represents a remarkable advance in 
primary prevention, is well-known, well-studied, and is in 
widespread use, some shortcomings have been identified, 
and there are no randomized controlled trials showing that 
its use improves outcomes.162,176,177 In some European regions 
and in low-risk populations the FRS may overestimate risk 
by a factor of 2.87, but underestimate it by a factor of 0.43 in 
high-risk populations.178 In women who sustained their 
first myocardial infarction, 95% had FRS scores in the low 
risk category, with the remaining 5% in the intermediate 
category.179 Using the NCEP-ATP III/Framingham risk 
estimator,153 17% of women in this cohort were ineligible 
for statins. According to the Framingham Heart Study, 39% 
of asymptomatic women over age 50 will eventually suffer 
a cardiovascular event, but the Third National Health and 
Nutrition Examination Survey180 indicates that just 0.9% of 
asymptomatic women will be in the high-risk FRS category.27 
Using the ATP III tool, for most combinations of risk factors, 
the majority of nonsmoking men ,45 years of age and nearly 
all women ,65 years of age will have 10-year risks ,10%, 
leaving many young individuals with sizeable risk burdens 
that remain untreated.181 FRS may predict satisfactorily in 
33% of women, and in 85% of men, for a combined predic-
tion rate of 63%.182 The lowest quoted is about 11%.183 The 
c-statistic, a number which reflects how a model discriminates Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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risk for future events, is 0.7–0.8 for the FRS,184 moderately 
good – a random coin flip is 0.5. Since CHD develops over 
decades, a 10-year horizon is insufficient to identify a sig-
nificant group of people with relatively low risk at the time 
of scoring,27,185 particularly young men.181,186 In one study, 
about 45% of enrollees between 32 and 47 years of age had 
a low 10-year predicted risk, but a predicted lifetime risk 
of $39%.187 Guidelines for primary prevention in women.188 
and the NECP Adult Treatment Panel III153 have endorsed the 
use of lifetime risk in younger adults.
According to data using coronary CT angiography, 
about two-thirds of women and one-third of men with 
substantial coronary disease may be missed when the FRS 
misclassifies them as low risk,192–194 because the initial 
physician is dissuaded from further screening.194 Over 75% 
of CHD events in men and over 90% of CHD events may 
be misclassified in women. In addition, more than 25% of 
patients who are being treated with statins may have no 
detectable plaque on such imaging.
The 2010 ACCF/AHA Guidelines for Assessment of 
  Cardiovascular Risk in Asymptomatic Adults32 assigned 
a Class I, LOE B recommendation for global risk scoring, 
advising that all asymptomatic adults without a clinical 
history of CHD should have their risk assessed using this 
method.
Recent discussions about screening for asymptomatic 
CHD and merits of scoring systems have raised unresolved 
issues beyond the scope of this review. For instance, how 
valid are claims of improved prediction beyond the FRS? One 
analysis showed that many such studies had limitations in 
design, analysis, or reporting that made improved predictive 
ability doubtful.195 It should be noted that the Reynolds 
Risk Score,156 which uses CRP levels and family history, 
and for which required metrics of adequate discrimination, 
calibration, internal validation, and reclassification have 
been satisfied, was not one of these. Another question is 
whether use of a risk-estimation system helps in risk factor 
reduction, as compared with graded treatment of each risk 
factor to guideline thresholds.196–197 Should asymptomatic 
patients be screened for atherosclerosis at all, since there is 
little evidence clinical outcomes improve by doing so, but 
instead simply administer a polypill to adults of a certain 
age or dispense free statins in fast-food restaurants? One 
recent commentary concluded it is worthwhile to screen.198 
The accompanying editorial199 observed that cardiovascular 
screening tests should be proven to prevent clinical disease, 
and that ability to predict or reclassify risk is secondary. 
One valid technique, they continued, is using the screen to 
identify subjects thought to be at high risk, and randomize 
them to treatment or control,200 as was done in the JUPITER 
trial.199 Papers that appeared before JUPITER was published, 
and the subsequent analyses that followed, mentioned 
insufficient improvement in reclassification when CRP was 
added to scoring systems.201,202 Results of large randomized 
clinical trials, such as JUPITER, provide strong, direct 
evidence of efficacy. Several recent discussions concerning 
merits of nontraditional risk factors are based upon statis-
tical parameters.203 In the clinic, practical reasons to use 
biomarkers are a) to refine a clinical decision that leads to 
an evidence-based change in therapy leading to improved 
quality of life, morbidity, or mortility, and/or b) to motivate 
a patient to understand, partner, and make lifestyle changes 
or adhere to drug or device therapies.
Use of multiple biomarkers to refine prediction of 
cardiovascular events has met with variable success.204–209 Out-
comes depend upon the markers selected, and is also a function 
of the population studied, particularly age, and the stage of the 
disease process. Recently multivariable regression was used 
in two middle-aged European populations totalling 10,466 
participants, adding a 30-biomarker score which included 
N-terminal pro-brain natriuretic peptide, C-reactive protein, 
and sensitive troponin I to a conventional risk model.208 A 
rise in 10-year risk estimation for cardiovascular events and 
significant improvement in reclassification was reported.
10-year risk vs lifetime risk
For the reasons discussed above, when risk scores are used 
to guide treatment, a considerable number of asymptomatic, 
low-risk individuals who may benefit from statin drug 
therapy over a period of time may not qualify. The current 
evaluation algorithm consists of dividing individuals without 
clinical heart disease into low-, intermediate-, and high-risk 
categories. Those with 10-year risks over 20% are begun on 
statin therapy after evaluation; intermediate risk individuals 
-10% to 20% – are given drugs for risk reduction and/or 
further noninvasive testing continues for additional strati-
fication; low-risk persons are generally advised about diet 
and lifestyle modification. Within this paradigm of targeting 
higher-risk individuals, approaches to improve the yield have 
included a) lowering the target LDL-C level; b) lowering 
thresholds for treatment in each risk group; c) greater use of 
imaging to identify those individuals misclassified by abso-
lute risk scoring; and d) replacing the 10-year risk horizon 
with lifetime risk.
The strengths of the relationships between individual 
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but with the time frame and gender.210 Lloyd-Jones and 
  collaborators have studied the use of lifetime risk for CHD 
extensively.27,52,165,168,185,210,211 These investigators noted that 
individuals younger than age 40–50 in a low-risk category 
with an initial FRS , 10% may have a surprisingly large risk 
burden and a high lifetime risk for CHD which may not be 
appreciated using current stratification techniques.27,211 For 
example, the Coronary Artery Risk Development in Young 
Adults Study found that .90% of individuals 32–47 years of 
age had a predicted FRS risk of ,10%, yet had a lifetime risk 
of $39%.187 According to NHANES data from 2003–2006, 
about 56% of American adults have a low 10-year risk but a 
high lifetime risk, only 18% have high short-term predicted 
risk, and 26% have both low short-term and low lifetime 
predicted risk.213 Moreover, just 8% of men and 14% of 
women enjoy optimal risk factors associated with a low 
lifetime risk for heart disease.213 Some of the errors in risk 
estimation by the FRS arise from unpredictable changes that 
occur in risk factors over time, such as blood pressure and 
insulin resistance, which may increase relatively quickly with 
age.214 Others arise from changes in the competing risk of 
death from causes other than CHD, such as tobacco use. Life-
time risks for CVD are comparable to those from extremely 
lethal diseases, and are generally higher than risks related 
to many cancers. At 50 years of age, however, the absence 
of traditional risk factors is associated with extremely low 
lifetime risk and significantly greater longevity.27,168 People 
with favorable risk factors enjoyed much lower lifetime risks 
for CVD death than those with unfavorable profiles (zero 
vs $ three risk factors, 20.5% vs 35.2% for men; 6.7% vs 
31.9% for women), along with longer survival (men, .35 vs 
26 years; women, .35 vs 28 years).168
A striking example of the limitations of current risk 
assessment in relation to actual lifetime risk was   provided 
by the work of Berry et al.187 They stratified 2,988   persons 
#50 years of age from the Coronary Artery Risk Development 
in Young Adults (CARDIA) study181,215–217 and 1,076 similar 
individuals from the Multi-Ethnic Study of Atherosclerosis 
(MESA)217–219 into three groups: low 10-year (,10%) risk/
low lifetime (,39%) risk; low 10-year/high lifetime risk 
($39%); and high 10-year ($10%) risk or diagnosed 
  diabetes mellitus (DM2). Among those with a low FRS, 
there were just as many participants with a high lifetime risk 
as a low lifetime risk, which implies that as many as half of 
individuals in this large low-risk group may fail to receive 
beneficial therapy.
In this investigation, coronary artery calcium (CAC) 
was also used to assess the degree of subclinical disease at 
baseline and after the study periods. In CARDIA, a CAC 
was performed at year 15 and year 20; in MESA, a CAC 
was performed at baseline, at about 22 months in 50% of 
participants, and at about 40 months in the remaining half. 
In addition, CIMT was performed in year 20 in the CARDIA 
study, and at baseline in MESA. In participants with a low 
10-year risk, the vast majority in the study, individuals 
with a low lifetime risk compared with a high lifetime 
risk had significantly smaller dimensions of common and 
internal carotid intima-media thickness, as well as a lower 
prevalence and progression of coronary artery calcium.187 
The differences in CIMT dimensions in younger adults 
were believed to ultimately correspond to considerable 
increases in cardiovascular risk over the years. Hence, 
exposure of individuals to higher risk factor intensities 
over a substantial period of time leads to accumulation of 
atheromatous changes, eventually reaching the threshold 
that produces clinical events at older ages.187,216 However, 
those individuals without risk factors at age 50 have a life-
time risk of CVD of approximately 5% over a generously 
extended lifespan.27
Consideration of lifetime risk is clearly important, 
not simply philosophically, but in treating patients in the 
real world. In view of these data, reports suggesting that 
statins are being overprescribed on the basis of 10-year risk 
estimations,220 or even a single CAC study,221 are of concern, 
and at the least, suggest further trials are needed. Not only in 
America, but globally, the facts indicate otherwise – that sta-
tins are underprescribed, and strikingly so, given the level of 
prevailing risk.222 Moreover, if low CAC scores only provide 
a “warranty” for a period of 4–5 years,223 retesting at such 
intervals to assess need for statins in patients who are likely 
to undergo additional diagnostic imaging could significantly 
raise the burden of radiation exposure, particularly if CAC 
screening widens.224–226
Nambi and Ballantyne,227 editorializing on the broader 
significance of these findings in risk stratification, also 
observed that within classically-measured low-risk cohorts 
of the “healthy” population, there was a significant difference 
in observed risk over 14 years of follow-up in their own 
work,228 and concluded that the evaluation of “low-risk” 
patients needs to be reassessed.
A new multi-level risk stratification proposal has been 
made using the FRS as the first tier, lifetime risk as the second 
filter, and CRP levels, with CAC and CMIT in a third tier to 
guide LDL-C-lowering therapy.227 These are the major tools 
that are considered important for risk assessment Recent data 
reflecting improved long-term safety and cost-effectiveness Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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of statins, even at FRS risks ≈10%, are additional reasons 
favoring statin therapy when predicted risk is in the lower 
end of the spectrum.76
The data mentioned above are consistent with   increasing 
awareness that the prevalence of ideal cardiovascular 
health in the population is low, and the greater number of 
cardiovascular events will ultimately rise among   individuals 
who are not in a high-risk category.2 The information 
  presented also adds to the growing body of evidence under-
scoring the importance of not only preventing development 
of risk factors at the earliest opportunity, but also screening 
sooner, stratifying more efficiently, and using intensive 
therapies to reduce risk.
Early, aggressive treatment  
is the new imperative
Early detection of atherosclerotic disease and refinement 
of risk assessment has been accompanied by a recent sea 
change in the thinking about the timing and aggressiveness 
of treatment of risk factors, in both ostensibly healthy 
individuals who are not investigated further than “routine” 
LDL-C levels, and those with established CHD.2,27,28,52,185,229–232 
The regression line for major statin studies shows that LDL-C 
reduction produces benefits in a linear fashion approaching 
“physiological” levels (see section below). The Cholesterol 
Treatment Trialists study suggested outcome improvement 
in statin-treated patients with baseline LDL-C ≈80 mg/dL.233 
The evidence for aggressive LDL-C lowering for high risk 
patients has been recently discussed elsewhere.234,235 Notably, 
Steinberg and coworkers138 called attention to the urgent need 
for earlier intervention in reducing risk factors, especially 
LDL-C, adding to the consensus.
Due to the evolution of disease-reactive medical care, 
escalation of clinical assessment and treatment usually 
follows the finding of either abnormal biomarkers or symp-
toms. Waiting until this occurs in CHD, with its long incuba-
tion period, is a prescription for certain failure of “primary” 
care. By the time elevations in LDL-C or CRP occur, espe-
cially at levels mandating therapy using current guidelines, 
the disease is widespread, relatively advanced but still often 
inaccessible to customary techniques used for detection. 
Consequently, the improbability of intervening early enough 
has generated skepticism about whether prevention is ever 
“primary”.236 For instance, studies using intravascular ultra-
sound (IVUS)237–242 and intracoronary optical coherence 
tomography243,244 amply demonstrate plaque in various stages 
of evolution invisible to routine coronary angiography due 
to limitations in resolution and view.
Proprotein convertase subtilisin-like/kexin type 9 serine 
protease (PCSK9) is a gene encoding PCSK9, a protease 
expressed in the liver and intestine in adults. The liver releases 
PCSK9 into the circulation, concentrations of which correlate 
with BMI, triglyceride, TC, and LDL-C levels, as well as 
blood pressure, fasting blood glucose, and gamma-glutamyl 
transferase levels. The protease is a molecular chaperone, 
bindling to the epidermal growth factor-like domain A of 
the LDL receptor, redistributing the LDL receptor from 
the plasma membrane to an endosomal/lysosome pathway 
for degradation.245 PCSK9 thereby regulates LDL receptor 
levels on the cell surface, particularly in hepatocytes.246 
Individuals with PCSK9 loss-of-function mutations have 
LDL-C levels about 28% lower than nonvariants.247,248 About 
3% of the population may have these variations. Such changes 
correspond to an 88% fall in risk for CHD events, nearly three 
times the reduction of a 5-year course of statins that reduces 
LDL-C comparably. On the other hand, gain-of-function 
mutations in PCSK9 results in diminished net expression 
of LDL receptors, producing a clinical picture resembling 
familial hypercholesterolemia.249,250 This experiment of nature 
suggests that favorable levels of LDL-C begun early, and 
maintained throughout life, are needed for optimum reduc-
tion in CVD events. Using the data from PCSK9 studies, 
Steinberg251 calculated that beginning statin therapy much 
earlier might double the yield and prevent 240,000 coronary 
events annually, based upon 2009 CHD mortality data.1 By 
any account, benefits associated with the use of statins and 
other preventive therapies over a 3.7–5.0-year span of a study 
would only be a fraction of the potential if applied over the 
total incubation period of CHD, 40–60 years.
In view of the above, aggressive intervention, when 
indicated, should be offered at the soonest opportunity 
to prevent disease progression and future coronary 
events.107,138,252,253 The longer lipid-lowering therapy 
continues, the greater the reduction in relative risk.233 Risk 
factors in youth are growing concerns among pediatricians. 
The ACCF/AHA 2009 Performance Measures for Primary 
Prevention of Cardiovascular Disease in Adults254 suggested 
that lifestyle measures begin at age 18.
Forrester255 emphasizes the difference between proof 
and inference, the need to begin treatment according to the 
pathogenesis of atherosclerosis rather than initial clinical 
manifestation, choose a lower physiologic LDL-C target, and 
adopt a new practical, but more effective, mindset. In view 
of the above, using CRP as a guide to earlier treatment from 
randomized clinical trial data, rather than by estimates of 
added increments in risk factor prediction using scoring Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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systems, is pertinent and timely.52,256 Rosuvastatin and 
atorvastatin in higher doses are the preferred agents for both 
LDL-C- and CRP-lowering ability.257,258
Statins in primary prevention
Measures used in primary prevention customarily include 
smoking cessation, diet modification, physical activity, weight 
management, correction of dyslipidemia (lowering LDL-C 
globally, targeting subfractions of LDL including Lp(a), low-
ering LDL-P or increasing the size of LDL particles, raising 
HDL-C globally, targeting subfractions of HDL, reduction 
of plasma triglycerides (TG) and other TG-rich atherogenic 
particles), reducing blood pressure, controlling diabetes and 
insulin resistance in related syndromes, use of aspirin, and 
treatment of comorbidities that commonly raise CHD risk, 
such as chronic kidney disease. The WHO MONICA project 
found that over half of non-fatal MIs in young people are 
attributable to smoking,259 and risk returns to baseline about 
5 years after cessation.260 For each cigarette smoked daily, the 
risk of MI rises by 5.6%.12 For every 38.7 mg/dL (1 mmol/L) 
fall in plasma LDL-C, there is a corresponding 21% reduction 
in cardiovascular events.261 A drop in systolic blood pressure of 
10 mmHg may result in a decrease of cardiovascular mortality 
of 20%–40%,262 which may be enhanced by using ambulatory 
blood pressure monitoring.263 A reduction in risk factors has 
contributed to the fall in the incidence of MI since 2000,264 
corresponding to a decrease in the prevalence of smoking from 
23.1% to 19.7%, and a drop in the prevalence of hypercholes-
terolemia from 17.0% to 16.3%. A 1% change in absolute risk 
may affect ≈2.2 million adults.265
effect of statins on plaque volume
The use of intravascular ultrasound (IVUS), with a greater 
sensitivity than coronary angiography, provides a direct and 
revealing method of assessing the effect of statin drugs upon 
coronary atheroma.237–241,266,267 In recent trials, there was a 
strong linear relationship between LDL-C values and ather-
oma progression rate, with a critical reversal level of LDL-C 
at 70 mg/dL. While the effects of statins upon lesions are 
evident, the extent of atheroma regression varies (Table 5). 
In the ASTEROID study,230,242,267 rosuvastatin 40 mg lowered 
LDL-C by 53% and raised HDL-C by about 15%, accompa-
nied by a significant reduction in atheroma volume in both 
coronary arteries that were angiographically normal as well as 
those with visible obstructions. Extension of these data with 
the use of quantitative coronary angiography (QCA) sug-
gested slowing of progression as well as regression of lesions 
in different segments of the coronary tree.240 Improvement 
in luminal dimensions, as measured with QCA, correlated 
with risk of coronary events and mortality.268,269 Changes 
in atheroma volume, stratified above or below a median 
change of -21.4% in CRP levels and -37.1% in LDL-C, was 
greatest in those with reductions in both LDL-C and CRP 
(-2 mm3), less when CRP fell but not LDL-C (-1 mm3), 
progressed when LDL-C fell but CRP was high (+2 mm3), 
and progressed the most when both LDL-C and CRP were 
high (+8 mm3).230
Serial computed tomography angiography (CTA) was 
performed in 32 older patients, 24 of whom took fluvastatin 
after the baseline CTA, with eight subjects who declined 
statin therapy serving as controls. After a median period 
of 12 months, plaque volumes were calculated in a 10 mm 
segment selected for comparison. Plaque volumes were 
significantly reduced in the statin-treated group.276
These data support a model in which atherosclerosis 
advances unpredictably in multiple sites at different 
rates. When LDL-C is lowered with statins, particularly 
rosuvastatin, the progression of the lesions may wane, some 
Table 5 Recent statin regression trials using coronary ivUS
Investigators Type Statin used Exam interval Primary endpoint Results (mean ± SD)
Petronio et al270 RCT Simvastatin 12 months Plaque volume  - 2.5 ± 3.0 mm3/mm
Control   1.0 ± 3.0 mm3/mm
Tani et al271 RCT Pravastatin 6 months % change in plaque volume -14.4 ± 23%
Control   1.1 ± 4.6%
ASTeROiD230,242 Not RCT Rosuvastatin 24 months Change in PAv -0.98 ± 3.15%
Takashima et al272 Not RCT Pitavastatin 6 months % change in plaque volume -10.6 ± 9.4%
Control   8.1 ± 14.0%
COSMOS273 Not RCT Rosuvastatin 18 months Change in PAv  - 5.1 ± 14.1%
JAPAN-ACS274 RCT Atorvastatin 8–12 months % change in plaque volume -18.1 ± 14.2%
Pitavastatin -16.9 ± 13.9%
Hirayama et al275 Not RCT Atorvastatin 28 weeks % change in plaque volume  - 9.4 ± 10.3%
80 weeks -18.9 ± 14.1%
Abbreviations: RCT, randomized controlled trial; PAv, percent atheroma volume.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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with complete regression. Whether these events are evident 
is also a function of the sensitivity of the technique used 
for assessment.277 Even when LDL-C is lowered drastically, 
approaching “physiological” levels, however, some lesions 
may still progress in many patients.278 This would include pri-
mary prevention patients, who may be so classified as a result 
of relatively insensitive techniques, but in whom the process 
is already under way. While unproven, preliminary evidence 
suggests that when CRP levels are elevated, especially in 
patients with metabolic syndrome, residual risk is likely to 
be high, a correlation may exist with CIMT, and the response 
to rosuvastatin may be greater.279,280
Statins recommended in guidelines
Several primary prevention guidelines from the USA, UK, 
and EU are available to assist clinicians, and the use of statins 
is typically recommended.12,153,158–160,188,281–285 According to the 
last NCEP-ATP III recommendations for primary preven-
tion, statins should be begun when LDL-C $190 mg/dL in 
individuals with low risk, is discretionary when LDL-C is 
160–189 mg/dL, and is not advised for ostensibly healthy per-
sons with LDL-C ,160 unless there are $ two risk   factors.286 
All are fairly high numbers, considering that 50 mg/dL might 
be “physiologic”, and soon NCEP-ATP IV will announce 
modified targets. The ACCF/AHA/ACP 2009 Competence 
and Training Statement on primary prevention287 succinctly 
reviews the essential role of lipid management, and advises 
that intensity of therapy match the individual risk for CAD 
in each patient. The overriding fact of life is that since the 
vast majority of people will not follow required lifestyle 
changes, patients with elevated cardiovascular risk will 
be treated with statins. Statin drugs have revolutionized the 
practice of cardiology over the last two decades, and there 
are no equals.
Analysis of statin use in primary 
prevention
There are seven systematic reviews examining the use of 
statins in primary prevention.288–294 Mills et al290 pooled 
results from 19 randomized trials to evaluate the effectiveness 
of statins in primary prevention. For 19 trials examining 
all-cause mortality, the relative risk (RR) was 0.93, and for 
17 trials, using major cardiovascular events, the RR was 
0.85. Overall, they concluded statins have a clear role in 
primary prevention of major events and mortality. Brugts and 
coworkers291 included ten trials involving 70,388 people, 34% 
women and 23% with diagnosed diabetes, all with risk factors 
but without established cardiovascular disease. Statin therapy 
lowered all-cause mortality (odds ratio [OR]: 0.88), major 
coronary events (OR: 0.70), and major cerebrovascular events 
(OR: 0.81). Mean follow-up time was 4.1 years. Since many 
trials did not consider death after a morbid cardiovascular 
event, the 12% risk reduction in mortality may have been 
an underestimate. Even though no clinical heart disease was 
identified, the pooled risk in the study population was high, 
and overall annual mortality was about 1.4%. Yet the relative 
risk reduction from statin use for primary prevention was 
comparable to that for secondary prevention.
A recent meta-analysis of the use of statins and all-cause 
mortality in high-risk primary prevention was performed by 
Ray et al.292 Eleven randomized controlled trials involving 
65,229 participants treated with statins for an average of 
3.7 years were found to have no statistically significant 
improvement in all-cause mortality. In those treated for 
primary prevention, average LDL-C levels fell from 139 
to 98 mg/dL (multiply by 0.0259 to convert to mmol/L). 
Compared to a mean placebo death rate of 11.4 per 1000 
patient-years, there were only seven fewer deaths for every 
10,000 patient-years of statin treatment.
The investigators emphasized the need to tease out 
patients with preexisting heart disease, because those 
patients would be the ones known to benefit from statin 
therapy. Although they were critical of other studies because 
of the short periods of study, the 3.7 year period of their 
meta-analysis was also relatively small. While the authors 
acknowledged statin efficacy in patients with diagnosed 
CHD, ie, for secondary prevention, they challenged statin 
use in low-risk patients when applying current prevention 
guidelines.31,293,294 Because this study was a meta-analysis, 
there was considerable heterogeneity in patient risk and 
statin use, and some of the data used were old. In addition, 
the limitations of meta-analyses are well-known, but apply 
equally to the analyses that found statins do improve 
mortality in primary prevention.290,291
The reaction to this study was muted, with the consensus 
believing that in a primary prevention cohort, the period of 
statin treatment involved was insufficient to show more, and 
that a reduction in CHD mortality, combined with the long 
incubation period of atherosclerosis evidenced by results of 
longitudinal studies, justified treatment with statins. Waiting 
years for treatment in primary prevention would be an 
imprudent delay, according to most observers.
Bukkapatnam et al295 focused their meta-analysis on 
women and included 6 studies, including JUPITER, totaling 
21,963 moderately hyperlipidemic women given statins 
for primary prevention. These investigators found that Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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the summary risk ratio for any CHD event was 0.78 (95% 
CI: 0.64–0.96; P = 0.02), but there was no demonstrable 
reduction in all-cause mortality or CHD deaths. They 
attributed the better results reported in JUPITER, in part, to 
the stronger predictive power of CRP in women than in men. 
However, Bukkapatnam,295 like Brugts and coworkers,291 
included data from the Primary Prevention of Cardiovascular 
Disease With Pravastatin in Japan (MEGA) study, conducted 
at 924 sites from 1994–2004.296,297 This trial randomized 
7,832 healthy men and women to pravastatin 10–20 mg with 
dietary modifications, or dietary modifications alone with 
a median follow-up of 5.3 years. MEGA found that statin 
therapy lowered CHD events by 33%, and relative risk for 
CVD events by 30%. Since the mean fall in LDL-C levels 
was just 11%, the statin produced an effect greater than would 
be expected from the reduction in LDL-C. While agreeing 
with the JUPITER trial discussed below, in that a statin 
was effective in lowering cardiovascular events in low-risk 
individuals without heart disease, some caveats are in order. 
At the time of the study, the prevalence of CHD in Japan 
was much less than in the countries in which JUPITER was 
conducted, and pravastatin in the doses used was consider-
ably less potent than rosuvastatin 20 mg.
Taylor and coworkers298 analyzed randomized controlled 
trials of statins in primary prevention with a minimum dura-
tion of 1 year, a follow-up of at least 6 months in adults, and 
also excluded #10% of participants with a history of CVD. 
Of the 14 trials included, 11 recruited patients with hyper-
lipidemia, diabetes, hypertension and microalbuminuria. 
Statins were associated with a 17% reduction in all-cause 
mortality (RR: 0.83, 95% CI: 0.73 to 0.95), lowering of 
combined fatal and non-fatal CVD endpoints (RR: 0.70, 95% 
CI: 0.61 to 0.79), with variation that was attributed to differ-
ent populations, statins employed, and reporting (Table 6). 
The investigators concluded that no significant harm or 
change in patient quality of life was caused by statins, and 
they reported sizeable improvement in all-cause mortality, 
CHD, and stroke events, as well as number of revasculariza-
tions. According to their review, there was selective reporting 
of outcomes, failure to report adverse events, and inclusion 
of participants with diagnosed CVD. Despite the evident 
positive benefit/adverse event ratio, they cautioned against 
use of statins in primary prevention patients thus: “below a 
1% annual all-cause mortality risk or an annual CVD event 
rate of below 2% observed in the control groups in the trials 
considered here – [statin therapy] is not supported by the 
existing evidence”. They further commented that there was 
insufficient demonstration of improvement in quality of life 
and cost-effectiveness associated with statin therapy.
Responses to these findings were immediate, strong, and 
largely opposed the authors’ conclusions. The accompany-
ing editorial36 cited a number of concerns. A major one 
revolved around the limitations inherent in uniting the diverse 
published data. Baigent,233 whose more complete work in 
the Cholesterol Treatment Trialists’ Collaboration was not 
considered, vigorously challenged the conclusions, citing the 
significant benefits of statin therapy in relation to safety that 
the authors readily discussed, yet ignored. Other prominent 
researchers termed the study biased, inappropriately using 
data limitations that were irrelevant to the central issue. In 
addition, the conclusions were diametrically opposed to the 
growing evidence that statins are in fact underprescribed, 
rather than overprescribed,222 and that less stringent criteria 
for the earlier use of statins would reduce total risk burden 
and subsequent events. Not only does the philosophy in the 
Cochrane review298 disagree with current evidence-based 
guidelines, but also argues against the rationale behind many 
current programs and public health initiatives, including 
those advocated by WHO and disadvantaged countries, now 
exploring implementing the distribution of polypills. Lack of 
inclusion of all pertinent studies, the weights given to those 
considered, and subsequent interpretations were all criticized. 
Finally, it was said that adverse reactions, such as cognitive 
defects and depression, were given credence without adequate 
and critical examination of the evidence.
Sources of controversy regarding statin 
use in primary prevention
The American College of Cardiology, American Heart 
Association, National Cholesterol Education Program, 
NHLBI, and European Society of Cardiology incorporate 
statins in recommendations for both primary and secondary 
prevention. About 75% of patients who take statins do 
so for primary prevention. Presently the studies forming 
the basis for this prescribing are short, from 5–7 years’ 
duration. The advice relies upon both scientific data and 
considered logical inference predicting that over a long 
period,   cholesterol reduction will be reflected in improved 
mortality outcomes. Several researchers believe the use of 
Table 6 Outcome improvements with statin therapy in primary 
prevention found in the Cochrane review298
Outcome Risk ratio (95% CI)
Total mortality 0.83 (0.73–0.95)
Fatal and nonfatal CHD events 0.72 (0.65–0.79)
Fatal and nonfatal stroke 0.78 (0.65–0.94)Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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statins over an extended period of time has underestimated 
potential.138,251,255,295,299,300
As mentioned, patients with CHD already have wide-
spread and advanced disease, but in general, the atherogenic 
process is fairly intense by the time a diagnosis is made. It is 
likely that the beneficial effects from statin therapy, particu-
larly mortality, take a longer period of time to demonstrate 
during the earlier stages of the disease, ie, during primary 
rather than secondary prevention. The chief benefit of statins 
in primary prevention is reflected in lower rates of nonfatal 
MI. Because mortality is low in such patients, the sensible 
interpretation is that the therapy was not begun sufficiently 
early, was not potent enough, or not continued long enough 
for mortality benefits to become significant. Similarly, one 
would not ordinarily expect, for instance, a striking reduc-
tion in mortality after 3.7 years when treating hypertension 
or smoking for primary prevention. The implication of the 
Ray and Taylor studies is that, for a mortality reduction, one 
should consider denying statins to patients until risk is high 
($20% 10-year FRS score), or the initial coronary event or 
diagnosis is made. This view is consistent with the NICE 
approach,283–285,301 but contrary to impressive data suggesting 
early and prolonged intervention is necessary. For the afore-
mentioned reasons, the results of these meta-analyses will 
probably not be practice-changing. In summary, the abso-
lute benefits of statins may be relatively small in a primary 
prevention population at low risk, and benefits are difficult 
to demonstrate short-term.
Given the economic constraints that exist in some 
countries, along with the political controversy surrounding 
health care delivery in the USA, the choice of medical 
services to be delivered now depends on factors other 
than science. Such issues may influence discussions in the 
academic literature. Most evidence indicates that population-
based use of statins is in fact cost-effective, but this is a 
function of population characteristics, cut-offs used, and the 
statin involved.302 The impact of generic atorvastatin was not 
considered in the Taylor study discussed above.
A large source of confusion about statin therapy 
  concerns adverse reactions. There is a substantial amount 
of information circulating about side effects that is simply 
not evidence-based. Beliefs about the prevalence, severity, 
management, and threat of such reactions underpin reluctance 
to treat by practitioners and create unfounded fear in patients. 
Muscle aches and minor musculoskeletal discomfort are 
among the most common of human complaints, but when 
patients are taking statin drugs, a connection is assumed, 
commonly fueled by an inordinate number of inaccurate 
discussions or anecdotes on the internet. Pertinent data do 
suggest that: a) side effects are “underreported” in published 
trials, in part an artifact of low myotoxicity due to strict 
screening and run-in periods; b) the incidence of side effects 
do not approach what is believed by some practitioners and 
consumers, eg, rates of ≈50% mentioned on the internet, 
compared to the actual ≈10%; c) life-threatening adverse 
reactions are extremely rare; d) most unwanted effects may 
be avoided and managed successfully; e) the incidence of 
intolerance and myotoxicity differs between statins; f) the 
benefits of statins far exceed those of adverse reactions, 
whereas other common drugs, such as aspirin, lack the same 
benefit/risk ratio in many settings.15,303–306
Statins and primary prevention  
in the elderly: a special population
Commenting upon a paper by Deedwania and coworkers in 
2007, which reported that intensive statin therapy was not 
superior to a moderate approach in suppressing ischemia on 
monitor recordings in the elderly,307 Gotto advised judicious 
application of statins in the elderly population pending further 
data,308 which are now available.
Statins are underutilized in treating the elderly with 
  cardiovascular risk, and a significant fraction of those 
individuals could benefit from statin therapy. Increasing 
age is a powerful risk factor, CHD is the most common 
cause of death in patients over 65 years, and over 80% 
of deaths due to cardiovascular disease occur in this 
population. The interaction of atypical presentations, 
multiple comorbidities, and polypharmacy may create 
uncertainty. Response to therapy is less predictable, 
while complications are more likely. Assigning causation, 
and prioritizing importance of pathophysiology from 
  clinical and laboratory findings become difficult. When 
the benefit-to-risk ratio of treatment alternatives become 
unclear, caution prevails. With increasing age, relative 
risks of high LDL-C levels decline. Muscle and other side 
effects of statins often affect older patients’   quality of life 
more than in the young.309 All may contribute to the low 
attainment of evidence-based targets in this   population.310 
Maroo et al311 revisited the issue by reviewing four studies 
in the elderly, and concluded that statins provided benefit 
in high-risk older patients, even though they might be 
more susceptible to unfavorable interactions. A large 
meta-analysis of ten randomized trials in individuals 
with risk factors but without a diagnosis of heart disease 
showed substantial benefit to the elderly in both risk factor 
reduction and improved survival.291 Wenger and Lewis,312 Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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noting that a lack of awareness of potential benefits and 
perceived safety issues contribute to undertreatment, called 
for greater use of guideline-recommended LDL-C targets. 
Long et al313 provide a recent authoritative discussion of 
details in individual trials.
Pletcher and Coxson314 discussed the possibility that 
TC and non-LDL-C were stronger risk factors in the young 
than the old, with relative risks of 0.44/1-mmol/L fall in TC 
at ages 40–49 vs 0.72 at ages 60–69,315 a relationship which 
they believed was also suggested in statin trials.233 Pletcher 
et al316 performed an analysis of age interaction of LDL-C 
and cardiovascular responses to statin therapy, and found that 
age may weaken statin effectiveness. Hayward,317 however, 
disagreed, citing the absence of age-dependent variation in 
responses to statins in primary prevention in a survey by 
NICE.283
Glynn and collaborators318 analyzed a subgroup of the 
JUPITER study of 5,695 persons over 70 years of age in the 
largest primary prevention statin study in this population. 
Compared to a cohort 50–69 years old, a greater propor-
tion were women and hypertensive, with fewer smokers 
and overweight individuals. Reductions in LDL-C and 
CRP in the rosuvastatin-treated group were comparable to 
those in younger participants. The two groups combined 
demonstrated a 44% relative reduction in the primary end 
point of nonfatal MI, nonfatal stroke, hospitalization for 
unstable angina, arterial revascularization, or confirmed death 
from cardiovascular causes. Even though their response to 
rosuvastatin was significant, 70% of the elders studied had 
an FRS . 10% and 65% were hypertensive. How much 
additional risk was conferred by elevated CRP levels was 
uncertain, since CRP levels rise with age.319 A large number 
of the subjects would have qualified for statin therapy using 
conventional guidelines. Therefore it was not surprising that 
in the older patients, the nonhypertensive subset did not ben-
efit from rosuvastatin therapy. Since the absolute reduction 
in risk was greater in the $70 year old group, the number 
needed to treat was 24, compared to 36 in the group aged 
50–69 years. Overall, the data confirmed that in higher-risk 
elderly patients, rosuvastatin should not be withheld for fear 
of adverse effects.
Residual risk remains a source  
of concern
In preventive cardiology, residual risk commonly refers 
to risk remaining after statin therapy has achieved LDL-C 
targets. However, residual risk also exists when multiple 
risk factors are being treated simultaneously. To be sure, 
traditional or “major” risk factors account for the greater 
portion of risk, and the population-attributable risk for 
each one are known.99 Non-lipid risk factors commonly 
coexist, and current practice guidelines recommend that 
all risk factors should be addressed for the best outcomes. 
Hence, a fuller definition of residual risk might be the 
vascular risk that persists after evidence-based targets are 
attained for dyslipidemia, hypertension, hyperglycemia, 
and inflammation.
Lipid-mediated residual risk during  
statin therapy
The average adult untreated LDL-C level in the USA 
is ≈130 mg/dL (3.4 mmol/L). Half of the individuals 
with “normal” levels ≈100 mg/dL (2.6 mmol/L) will have 
atherosclerosis by age 50.320 In the Pravastatin or   Atorvastatin 
Evaluation and Infection Therapy (PROVE-IT),   aggressive 
lowering of lipids used only prevented ≈20% of cardiac 
events.321 There is ≈30% relative risk reduction with aggres-
sive statin therapy using current guidelines, resulting in 
about 0.5% lowering of major adverse cardiovascular events 
(MACE) per mg% reduction in LDL-C, amounting to a 24% 
MACE reduction per each 1 mmol/L fall in LDL-C.234 This 
leaves a yearly ongoing incidence of MACE of ≈9% in such 
patients despite aggressive statin therapy.233 PROVE-IT322 and 
a dual target analysis of JUPITER278 suggested that further 
reduction of LDL-C to ≈40 mg/dL may safely lower event 
rates even more. In the major well-known statin studies 
residual risk averages 65%–75%, and in studies aggressively 
lowering LDL-C to ,100 mg/dL, residual risk persists. For 
this reason, simply reducing LDL-C to lower levels is of 
value, but residual risk is still significant. Use of more potent 
agents, such as rosuvastatin, with somewhat greater ability to 
raise HDL-C, may also be of benefit. For instance, in early 
statin studies using pravastatin, residual risk was ≈76%; use 
of rosuvastatin in the JUPITER trial was associated with a 
residual risk of 56%, certainly an impressive improvement.
Using intravascular ultrasound, Bayturan et al found 
that in about 20% of patients treated intensively down to a 
mean LDL-C of 58.4 mg/dL (1.5 mmol/L), plaque volume 
still increased.278
A portion of residual risk arises from atherogenic 
particles other than LDL-C, especially components of 
non-high-  density lipoproteins (non-HDL). These include 
intermediate density lipoprotein, very low-density lipoprotein 
(VLDL), chylomicron and VLDL remnants, and lipoprotein 
(a). High triglyceride levels, low amounts of HDL-C, and 
defective HDL also contribute to risk. In the PROVE IT-TIMI Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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22 trial,323 lower on-treatment CV risk was associated with 
TG ,150 mg/dL. Cardiovascular event rates are higher when 
HDL-C is low in statin-treated patients,233 while the additive 
risk of low HDL-C values is greater when LDL-C is low.324,325 
The EPIC (European Prospective Investigation Into Cancer 
and Nutrition)-Norfolk study326 established that, independent 
of LDL-C levels, individual non-HDL-C $30 mg/dl higher 
than LDL-C predicted increased CHD risk, and triglyceride 
(TG) levels .150 mg/dL, or TC/HDL-C ratio .5 was asso-
ciated with elevated risk for CHD. Carey et al327 conducted 
a hospital-based, case-control study in patients at optimal 
LDL-C levels and also found strong and synergistic effects 
of high TG and low HDL-C levels upon CHD risk in patients 
with optimal rather than higher LDL-C, even ,70 mg/dL. 
Specifically, there was a rise of ≈20% in risk associated 
with a 23 mg/dL increment in TG, and an increase in risk 
of ≈40% when HDL-C was 7.5 mg/dL lower. In patients 
who have achieved an LDL-C #70 mg/dL, Núñez-Cortés 
et al328 estimated that an increase in HDL-C of 1 mg/dL 
would be expected to reduce the risk of subsequent MACE 
by ≈1.1%.
While most of the risk associated with obesity is mediated 
through hypertension, dyslipidemia, and hypertension, 
  obesity itself is an independent risk factor. The pathoge-
netic events leading to raised cardiovascular risk in over-
weight and obesity are complex, heavily researched, remain 
ill-  understood, but extend beyond metabolic, hormonal, 
and cytokine dysregulation329–343 to include endothelial 
dysfunction, local pericardial fat accumulation,341,342 liver 
involvement, and adrenergic disturbances.315 Even when 
evidence-based targets are attained in all areas of traditional 
risk factors, residual risk persists. In diabetics, the risk is 
greater than is accounted for by the degree of separate risk 
factors. Inability to eliminate risk further by additional 
lowering of blood pressure,345 glucose,346 and through 
  combination anti-lipid treatments347,348 may be explained by 
a complex biochemical web producing risk in diabetes.349 
For these   reasons, lifestyle modification and exercise remain 
fundamental   cornerstones in the management of risk in these 
populations. In patients with diabetes and insulin-resistance 
syndromes, a “normal” baseline LDL-C sometimes creates 
reluctance to begin or intensify statin therapy, but in such 
patients with clearly elevated risk, benefits occur inde-
pendently of initial LDL-C levels, and they should not be 
withheld. The sources of residual risk and management in 
patients with atherogenic dyslipidemia is further discussed 
by Hermans and Fruchart.350
High-density lipoprotein (HDL)
In general, a rise of 1 mg/dL in HDL-C is associated with a 
3% lower CHD risk in women, and a 2% lower CHD risk in 
men.351 Epidemiological studies associate low HDL-C levels 
with an increase in the rates of myocardial infarction (MI), 
stroke, and mortality. High HDL-C levels ($60 mg/dL) 
are protective, whereas a low HDL-C level (#40 mg/dL in 
men, #50 mg/dL in women) is an independent risk factor 
for future cardiovascular events; some guidelines advocate 
raising low HDL-C levels, especially in high-risk patients. 
In general, raising HDL-C levels is considered beneficial 
for much of the population.241,352,353 NHANES 2003–2004354 
reported the mean HDL-C in the USA was 54.3 mg/dL, and 
was low in 27% of all NHANES participants, and in 35% 
of NHANES subjects with CVD. Hence prevalence of low 
HDL-C is common, affecting about one-third of the American 
population, with an HDL-C , 20 mg/dL found in ≈0.5% 
of men and ≈0.25% of women. HDL-C levels depend upon 
genetic and environmental factors, with lifestyle choices, 
including the use of alcohol and tobacco, among the revers-
ible factors. As a result of the rise in the prevalence of obesity, 
diabetes, and the metabolic syndrome, the mean HDL-C in 
patients presenting with an acute coronary event has fallen 
during the past 10 years to 38 mg/dL.355
In 12,339 subjects without CHD at baseline in the ARIC 
study,356 10-year risk was lowest for those with LDL-C values 
in the lowest quintile (men, 95 mg/dL, women, 88 mg/dL) 
and lowest in the highest quintile for HDL-C (men, 62 mg/dL, 
women, 81 mg/dL). When adjusted for LDL-C, HDL-C, and 
TG, each 1 standard deviation rise in HDL-C, 15 mg/dL, 
was linked to relative CHD risks of 0.64 in men and 0.69 in 
women. The Emerging Risk Factors Collaboration,357 a 
meta-analysis with over 300,000 subjects without CHD at 
baseline, found that rates of CHD per 1000 person-years in 
the lowest and highest tertiles of baseline lipid distributions, 
respectively, were 2.6 and 6.2 with triglyceride, 6.4 and 2.4 
with HDL-C, and 2.3 and 6.7 with non–HDL-C. On the other 
hand, in a meta-regression analysis that included 108 random-
ized trials of lipid reduction upon outcomes358 with about an 
equal number of participants at risk of cardiovascular events, 
simply raising the amount of HDL-C by 1.7 mg/dL (3.6%) 
had no effect upon CHD morbidity, CHD mortality, or total 
mortality after adjusting for the LDL-C levels.
In the Air Force/Texas Coronary Atherosclerosis Preven-
tion Study (AFCAPS/TexCAPS), the ratio apolipoprotein 
B (apoB)/apolipoproteinA-I (apoA-I), discussed further 
below, predicted cardiovascular risk better than LDL-C or Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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HDL-C.359 Of all available statins, rosuvastatin simultane-
ously produces the greatest increases in HDL-C and apoA-I, 
together with the best reductions in LDL-C and apoB.360,361 In 
the ASTEROID trial,241 HDL-C levels were inversely related 
to CHD progression during statin therapy as assessed using 
quantitative coronary angiography and using intravascular 
ultrasound (IVUS).351 Negi and Ballantyne362 plotted the 
change in percent diameter stenosis per year vs the on-
treatment HDL-C level in an angiographic statin trial, which 
described a linear, monotone inverse relationship. The relative 
effects of rosuvastatin vs atorvastatin on atheroma volume, 
employing IVUS, is being compared in the Study of Coronary 
Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin 
vs Atorvastatin (SATURN), now in progress.363
HDL biology-function, quantity,  
and quality
HDL is a mixture of heterogenous particles synthesized in the 
liver, jejunum, on the surfaces of macrophages, and in serum. 
They vary in size, density (between 1.063–1.21 g/mL), 
composition, surface charge, and function. HDL shape 
ranges from discoid to spherical, depending upon its lipid 
composition. The biology of HDL is more complex than 
that of LDL, and capable of slowing atherosclerosis through 
several mechanisms. The number of regulators – genetic 
polymorphisms affecting synthesis of apoproteins, receptors, 
enzymes that remodel lipoproteins, and inflammatory markers 
that determine HDL-C levels, maturation, and   function – are 
staggering, but multiple steps and regulators simultaneously 
provide additional therapeutic opportunities.364 Over 75 
different proteins are found within HDL populations that 
are concerned with lipid metabolism, complement activa-
tion, acute phase response; and protease inhibition.365 Within 
the total HDL-C weight, the subfractions function differ-
ently, each with a specific biological function366 which is 
partly dependent upon the triglyceride level. The complex 
proteasome and lipidosome of HDL particles, in constant 
flux, may alter individual HDL particle function as its com-
position changes. The most important protein component is 
apolipoprotein A-I (apoA-I), accounting for approximately 
70% of HDL protein mass, with apoA-II comprising 15% 
to 20%. Hence, apoA-I is sometimes considered a surrogate 
for HDL-C. Physically, apo-AI occupies about 85% of the 
surface of HDL, and it is believed that HDL size is modulated 
by a twisting motion of the apo-AI molecule. Cross-linking 
chemistry and mass spectrometry data suggest that apo-AI 
adopts a symmetrical cage-like structure to hold the lipid 
cargo. HDL interacts functionally with scavenger receptor 
class B type I (SR-BI), a cell surface glycoprotein, and 
the resulting SR-BI signaling is important in hepatocytes, 
endothelial cells, macrophages, and platelets.367
The most significant atheroprotective function of HDL is 
reverse cholesterol transport (RCT). Preβ1-HDL, the lipid-
depleted form of HDL, receives cholesterol from arterial 
plaque via macrophage ATP-binding cassette transporter 
ABCA1. In these enlarging particles, apoA-I accepts more 
cholesterol from the periphery, with the assistance of lipo-
protein lipase and cholesteryl ester transfer protein (CETP), 
to become mature α1-HDL particles.368 Eventually choles-
terol is returned to the liver or to apolipoprotein B (apoB)–
containing cholesterol-acceptor particles.369 ApoA-I in HDL 
plays a major role in RCT: underexpression of apoA-I is 
antiatherogenic, and small peptides that mimic some proper-
ties of apoA-I may impede atherosclerosis and improve HDL 
function, even without a rise in HDL-C levels.370 Raising 
apoA-I production also increases the the number of preβ1-
HDL particles and is antiatherogenic. Various functions of 
HDL are summarized in Table 7.
These properties collectively provide significant pleio-
tropic protection against atherothrombotic disease, not only 
by modulating lipids, but also through non-lipid antioxida-
tive, antiinflammatory, and antithrombotic mechanisms. 
Rosuvastatin produces the greatest rise in HDL-C compared 
to other statins, and for this reason may be favored, particu-
larly in women, or in patients who are overweight, smokers, 
or glucose intolerant, all of which depress HDL-C levels. 
Proof, however, of improvement in clinical outcomes when 
HDL-C is raised in these settings, is presently lacking, and 
awaits data from ongoing studies.
“Dysfunctional” HDL
Unfortunately, quite apart from the torcetrapib experience, 
higher HDL-C levels, as mentioned above, are not always 
associated with improved cardiovascular outcomes.377–381 
When estrogen and progestins were administered in the 
Women’s Health Initiative,382 HDL-C rose 7.3%, but CHD 
risk increased by 29%. During pro-oxidative and inflamma-
tory states, including CHD, diabetes, metabolic syndrome, 
infections, surgery, active rheumatic conditions, chronic 
kidney disease, obstructive sleep apnea, and other diseases, 
HDL may become “dysfunctional”.383 Rather than function 
as an antioxidant, it may even result in a pro-oxidant, 
  pro-inflammatory phenotype;384,385 HDL from patients with 
CHD may promote LDL oxidation.386 HDLs from individuals Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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recently diagnosed with CHD, but not yet treated with   statins, 
have a unique protein cargo, compared to HDL found in 
healthy control subjects.365,387 There are many molecular 
mechanisms through which HDL may become dysfunc-
tional, including changes in protein composition, change in 
antioxidant activity, overexpression of apoA-II, infectious 
processes and toxins, enzymatic modification of constituent 
HDL proteins and/or lipids, oxidation, interaction with 
inflammatory mediators, and others.
Common in vitro processes that may adversely affect the 
cholesterol efflux property of normal HDL are oxidation, 
  preventing the maturation of HDL, advanced glycation of 
HDL, and chlorination and nitration of HDL by myoper-
oxidase (MPO). ApoA-I, the primary protein constituent 
of HDL, is a selective target for MPO-catalyzed nitration 
and chlorination in vivo. Such MPO-catalyzed oxidation 
of HDL and apoA-I selectively inhibits ABCA1-dependent 
cholesterol efflux from macrophages, which in turn promotes 
oxidation of LDL.386,388 Other processes during inflamma-
tion that may impair HDL function are increased HDL 
catabolism,   displacement of ApoA-I from HDL by the 
acute phase reactant serum amyloid A (which also impairs 
activity of lecithin:cholesterol acyltransferase, paraoxo-
nase, and Lp-PLA2),389 lower synthesis of apoA-I390,391 and 
decreased activity of platelet-activating acetylhydrolase 
and lecithin:cholesterol acyltransferase (LCAT).392,393 
  During acute phase reactions beneficial proteins in HDL 
particles other than ApoA-I may also be may exchanged for 
fibrinogen or soluble lipoprotein associated phospholipase 
A2. In addition, changes in proteins that are not constituents 
of HDL, but are concerned with HDL metabolism, such 
as SR-BI, may be proatherogenic even when HDL-C is 
increased.394 Finally, patients with   polymorphisms in the 
promoter for hepatic lipase have higher HDL-C levels but 
raised risk for CHD.376 Hence individual genetic mutations 
and metabolic status may result in critical loss of HDL 
function. Other genetic variations in which there may be 
a divergence of HDL-C levels and the anticipated inverse 
CHD risk are discussed by Tall et al.395 Treatment of 
patients with nongenetic dysfunctional HDL with statins396 
or statins combined with niacin397 may partially reverse the 
impairment in HDL function. Sorrentino et al398 reported 
that HDL from diabetics was deficient in their ability to 
promote endothelial progenitor cell-dependent endothelial 
repair, increase endothelial nitric oxide expression, and 
produce endothelium-dependent relaxation. These defects 
were associated with raised HDL lipid peroxidation and 
MPO content, and could be improved with niacin therapy. 
Exercise is a frequently-overlooked, effective modality to 
partially repair defective HDL and raise HDL-C levels.
Interestingly, CRP and MPO have been linked together 
as predictors of prognosis in a number of cardiovascular 
outcome studies.398 CRP has also been shown to stimu-
late MPO release in human polymorphonuclear cells and 
Table 7 Some functions of high-density lipoprotein (HDL)
•   Participation in reverse cholesterol transport of cholesterol, through the ATP-binding cassette (ABC) transporters and additional mechanisms, is 
the most important vasculoprotective function. Since peripheral cells cannot metabolize cholesterol, it will accumulate unless carried back to the 
liver for disposal. Heterogeneous HDL particle subfractions are continuously exchanging moieties and interacting with other lipoproteins, lipolytic 
enzymes (hepatic and endothelial lipases), and transfer proteins (lecithin:cholesteryl acyltransferase, phospholipid transfer protein). A major feature 
of HDL remodeling involves transfer of cholesteryl ester from cholesterol-rich HDL in exchange for triglycerides from apolipoprotein B (apoB)–
containing cholesterol-acceptor particles.371 While the atherosclerotic process is affected by cholesterol efflux capacity from cultured macrophage 
foam cells, this property may be independent of the HDL-C level,372 related more to its function, ie, quality, rather than quantity.373
•   Protection and support of endothelium, through inhibition of monocyte chemotaxis, adhesion molecule expression, and enhanced nitric oxide 
production.365
•   Prevention of LDL oxidation, involving two redox active methionine centers in apoA-i, paraoxonase-1 (PON-1) and paraoxonase-3,374,375 as well as 
other component antioxidant enzymes contained in HDL, such as glutathione peroxidase, and platelet activating factor acetylhydrolase).
• Promotion of efflux of oxidized LDL from macrophages.
• Antiproliferative actions, particularly reducing apoptosis in macrophages.
• Anticoagulation, via inhibition of factors Va and VIIa and promotion of urokinase-dependent fibrinolysis.
• inhibition of platelet activation and aggregation, which protects the endothelium and inhibits thrombosis.
• Augmentation of prostacyclin synthesis through activation of cyclooxygenase-2.
• Stimulation of endothelial cell migration and recruitment of endothelial progenitor cells at sites of endothelial injury.
• Reduction of inflammatory mediator expression.
• Participation in the immune system, through component complement proteins.376
• inhibition of atherogenic remnant particle production, by maintaining vLDL-triglyceride homeostasis.
• Promotion of glucose uptake and fatty acid oxidation, tempering any rise in insulin resistance, along with upregulation of pancreatic insulin secretion.
•   Mediation of vascular protection ascribed to 17β-estradiol, the most potent endogenous estrogen, via enhanced HDL-induced endothelial nitric 
oxide synthase 3 activity to increase nitric oxide release.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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monocytes in vivo, and may have significance in patients 
with acute coronary syndromes.400
With insulin resistance, the metabolic syndrome, 
acute inflammation, and in hypertriglyceridemia, more 
triglyceride-rich HDL is produced as a result of enhanced 
CETP activity. A number of events may lead to lower 
HDL-C and HDL-P, including remodeling of triglyceride-
enriched HDL by hepatic lipase, resulting in enhanced 
binding, internalization, and degradation of HDL, as well 
as instability of these moieties with loosely-bound apoA-I, 
without major roles of either SR-BI or proteoglycans.401–403 
Moreover, the triglyceride-rich HDL uptake by SR-BI may 
be deficient, reducing the effectiveness of reverse cholesterol 
transport.366 In diabetes, the typical lipid phenotype includes 
small, dense HDL particles, enriched with triglycerides and 
depleted of cholesteryl esters, which have lost 20%–50% of 
their antioxidative capacity.404 This finding correlates with 
elevated levels of 8-isoprostanes, robust markers of oxidative 
stress.405,406 Since patients with metabolic syndrome will not 
typically progress to overt diabetes unless there is pancreatic 
beta-cell failure, the recently-described potential role of defi-
cient and defective HDL in the future loss of insulin secretion 
by beta cells through ABC transporters is of importance.407 
In addition, insulin resistance may increase HDL catabolism 
and renal excretion, adding to the difficulty of raising HDL-C 
levels in such patients.
HDL as a component of the immune 
system
Proteomic analysis of HDL365 has identified more proteins 
involved with acute-phase response than are associated with 
lipid metabolism, consistent with the view that a major role 
of HDL is to inhibit inflammation. Moreover, a number 
of proteins within HDL regulate complement activation, 
which is known to have a role in atherogenesis.408 Potential 
triggers of complement activation within atherosclerotic 
lesions include immune complexes, CRP, oxidized and 
glycated lipoproteins, apoptotic cells, cholesterol crystals, 
and possibly dysfunctional HDL.409 Circumstantial evidence 
supports the hypothesis that HDL not only is responsible for 
cholesterol trafficking, but also plays a part in the immune 
system protecting against infection. Such a system envisions 
HDL assisting in the removal of apoptotic cells from inflamed 
and/or infected sites. Thus, in addition to the removal of 
cholesterol from macrophages, the additional exchange of 
proteins and lipid moieties between HDL and macrophages 
may regulate inflammation. Exposure of macrophages to bac-
terial endotoxin lipopolysaccharide (LPS) downregulates the 
transporters ABCA1 and ABCG1, thereby suppressing their 
ability to efflux cholesterol.410,411 Any inflammatory mediators 
that use the same signaling pathways as LPS would inhibit 
reverse cholesterol transport. Direct proof was provided by 
administering LPS to human volunteers, which resulted in 
stimulation of acute phase reactants serum amyloid A and 
CRP. These changes were accompanied by remodeling of 
HDL, which became less able to accept cholesterol.409 Further 
confirmation came from septic patients, in whom inflamma-
tion reduced the ability of HDL to accept cholesterol by 73% 
as compared with controls.412 This proposal also fits with the 
larger notion that lipids are capable of activating circulating 
immune cells which may contribute to the pathogenesis of 
atherosclerosis.413
Heritability of HDL-C levels
About 40%–60% of HDL-C levels are heritable.414 Aside 
from the ≈40 genetic polymorphisms in the APOA1 gene 
which may contribute to variation in HDL function, genetic 
variation in genes encoding the many other substances 
involved in HDL metabolism, particularly CETP, appears 
to be clinically relevant. Genome-wide association studies 
demonstrate the strongest associations with HDL-C are found 
among CETP single nucleotide polymorphisms. For instance, 
the B2 allele of the TaqIB polymorphism of CETP may 
be associated with recurrent cardiovascular events.415 The 
strength of CETP gene polymorphisms upon HDL-C is also 
uninfluenced, at least in high risk patients, by dietary interac-
tions, eg, the Mediterranean diet, or with obesity, smoking, 
diabetes, or alcohol use.380 Although dysfunctional HDL may 
exist at all HDL-C levels, the association of high HDL-C with 
high CRP levels, especially in post-infarction patients, may 
be characterized by larger HDL particles, higher apoA-I and 
serum amyloid A levels, and suggests that further evaluation 
of HDL quality is warranted.414 The full clinical significance 
of dysfunctional HDL awaits greater use of a relatively new 
cell-free laboratory evaluation of HDL function.393,416
An interesting application begins with an analysis from 
the INTERHEART study, which reported that South Asians 
have an unusually high prevalence of low HDL-C levels.416 
In South Asian immigrants, in whom metabolic syndrome 
is frequent, conventional risk factors, insulin resistance, 
and components of the metabolic syndrome, are insuffi-
cient to account for their raised CHD risk.418 Using CIMT 
and a novel cell free assay and HDL inflammatory Index, 
Dodani et al419 found that 70% of south Asian immigrants 
with subclinical CHD had dysfunctional HDL. It is hypoth-
esized that a unique combination of genetic predisposi-
tion, high carbohydrate intake, lack of exercise, tobacco 
use, and low birth weight due to maternal malnutrition Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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suppresses the activity of ∆6 and ∆5 desaturases and low-
ers the levels of anti-inflammatory essential fatty acids in 
South Asians.420
Comprehensive discussions about HDL biogenesis, 
life cycle and function, are available elsewhere in greater 
detail.364,382,403–406,421–425
Potential of HDL modification  
to lower risk
Interest in raising HDL-C levels, or improving HDL 
function, continues in the ongoing search for methods to 
close the residual “risk gap”.403,424,426 The most   effective 
available agent is niacin, but practical problems with flushing 
limiting the use of this agent are well-known. The failure 
of proatherogenic cholesteryl ester transfer protein (CEPT) 
inhibitor torcetrapib, which produced a 70.3% rise in HDL-C 
levels, but an increase in CHD of 21%, was due in large part 
to off-target toxicity characterized by aldosterone-  associated 
hypertension, hypokalemia, and elevations in serum bicar-
bonate levels.427–429 However, that disappointment has 
recently been replaced by some optimism. A preliminary 
report of the study Determining the Efficacy and Tolerability 
of CETP Inhibition with Anacetrapib (DEFINE) indicates 
that anacetrapib, another CETP inhibitor, produces an out-
standing 138% rise in HDL-C levels, a 39.8% reduction 
in LDL-C, does not raise aldosterone levels, and may be 
associated with improved outcomes.430–435 The beneficial 
lipid actions appear to be additive with those of statin drugs. 
CETP mediates exchange of lipids between HDL particles 
and other lipoprotein fractions. It remains to be shown 
whether the HDL produced by anacetrapib is biologically 
normal, cardiovascular events will be reduced, and safety 
will be demonstrated in a large randomized trial, which is 
now under way.430 Dalcetrapib is a second nontoxic CETP 
inhibitor under investigation with potential to raise HDL-C 
and lower LDL-C.
An additional approach involves stimulating the endog-
enous production of apoA-I in patients with CHD in order 
to raise preβ1-HDL particle number and enhance RCT. 
A new oral agent, RVX-208, selectively induces nuclear 
transporter factors to induce hepatic ApoA-I   synthesis, and 
has been shown to increase blood levels of both preβ1-HDL 
and mature α1-HDL. In the first report from the ASSERT 
(ApoA-I Synthesis Stimulation Evaluation in Patients 
Requiring Treatment for Coronary Artery   Disease) study,436 
RVX-208 therapy raised apoA-I and HDL-C levels   modestly, 
up to 5.6% and 3.2%–8.3% respectively,   accompanied by 
an 11.1% to 21.1% rise in large HDL particles, actually less 
than is associated with niacin therapy. Unfortunately there 
were also significant increases in hepatic transaminase lev-
els, which may limit the future of this   particular agent.437
While an additive effect of maximizing HDL-C levels 
along with reductions in LDL-C has been appreciated for over 
a decade,438 the real potential of combining statins with other 
agents remains unknown. A beneficial effect upon atheroma 
burden was suggested in ASTEROID230 and upon CIMT in 
ARBITER 6-HALTS439 when using niacin.
Recently the AIM-HIGH trial440 was stopped early by 
the NHLBI after 32 months. In this study, 3414 patients 
with cardiovascular disease, low HDL-C and high TG levels 
were given either simvistatin and a placebo, or simvistatin in 
adjusted doses and extended-release niacin 1500–2000 mg, 
with 515 of the patients in the treatment cohort receiving 
ezetimibe 10 mg if needed, to achieve LDL-C levels of 40 to 
80 mg/dL. Although niacin lowered TG and raised HDL-C 
levels as expected, there was no effect on a composite end-
point of fatal or nonfatal MI, stroke, hospitalization for acute 
coronary syndrome, or need for revascularization procedures. 
A small, unexplained increase in the rate of ischemic strokes 
in the niacin group also played a part in the decision to halt 
the study. It is important to note that the patient population 
had well-controlled on-treatment LDL-C levels. General-
izing these findings to other patient groups, particularly to 
those with higher LDL-C levels commonly encountered, is 
presently premature. Full interpretation awaits analysis and 
publication of the AIM-HIGH study data. Hopefully, the 
results of the more definitive HPS2-THRIVE study441 now 
in progress, involving 25,673 participants, will help answer 
some of the many questions raised. 
However, these disappointing results suggest, as has been 
noted previously, that beneficial changes in surrogates such 
as risk factors do not necessarily mean improved outcomes, 
and now have significant implications for future drug inves-
tigations. In addition, the FDA currently approves new drugs 
based upon biomarker end points.
Despite the well-documented association of high HDL-C 
levels with cardiovascular protection, and low HDL-C 
values with poorer outcomes in atherothrombotic disease, 
pharmacological manipulation of global HDL-C levels is 
complex, probably not sufficiently specific with respect to 
the HDL molecule, and differs with each agent used. 
Other lipid targets: non-HDL-C  
and lipid fractions
Compared to estimates of LDL-C, does measurement of 
apolipoproteinB, total cholesterol/HDL, apoB/apoA-1, Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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or non-HDL-cholesterol (non-HDL-C, total cholesterol – 
HDL-C), offer any advantage as a predictor, and as a thera-
peutic target? Early Framingham data showed LDL-C 
was predictive, but total cholesterol/HDL-C442 and apoB/
apoA-1 are equal, if not better, predictors.443 Ratios show 
a stronger correlation with cardiovascular events than does 
LDL-C.99,444,445 Since over half of all such events occur 
in apparently healthy persons without abnormal LDL-C 
levels, thinking beyond LDL-C has been a recent goal in 
order to improve both predictive ability and reduce residual 
risk. The lay press frequently mentions that up to 77% 
of patients with cardiac events have normal cholesterol 
levels, to which there is no satisfactory reply. Moreover, 
the relatively high proportion of statin-treated patients 
hospitalized for new events, even though a significant 
number of them are already at LDL-C goals, is a further 
embarrassment.355
The estimated LDL-C derived from the Friedewald 
formula not only introduces error, and does not reflect all 
atherogenic particles, but the need for a fasting sample is 
inconvenient. Without the need to fast, non-HDL-C is easily 
derived from the prevalent lipid profile.
Non-HDL-C is strongly associated with cardiovascular 
events446,447 and is sometimes considered a proxy for apoB. 
When calculated from the standard lipid profile, it measures 
the amount of cholesterol contained in all atherogenic 
lipoproteins (excluding any proatherogenic HDL) – LDL, 
IDL, VLDL, and Lp(a). On the other hand, apoB reflects 
the number of circulating atherogenic particles, and is 
expressed in mg/dL. LDL particle number (LDL-P) is the 
number of LDL particles per liter of plasma, expressed in 
nmol/L. In healthy people non-HDL-C may equal apoB 
and LDL-P for accuracy in risk assessment.448,449 However, 
when HDL levels are low, triglyceride values are high, 
and in patients with diabetes or metabolic syndrome, 
LDL-P and apoB are much better indices of cardiovascular 
risk.359,440–452 Compared to the 1970s and 1980s, an increas-
ingly greater proportion of patients being evaluated are 
overweight, have higher triglyceride (TG) levels and small, 
dense LDL particles. With an abundance of triglycerides 
and TG-rich particles, these patients overproduce VLDL 
in the liver, which accounts for the increase in small, 
dense LDL and their low concentrations of HDL-C.453,403 
As the number of individuals with visceral adiposity in the 
  population – now at 53% – increases, the accuracy of stan-
dard lipid profiles to predict risk diminishes, particularly in 
overt diabetics, since the discordance between LDL particle 
number and LDL-C enlarges as triglyceride values rise 
above ≈160 mg/dL. An American Diabetes Association/
American College of   Cardiology consensus statement454 
considered this discordance and some limitations of the 
method. A more recent position statement by the American 
Association for Clinical Chemistry favored LDL-P as an 
accurate indicator of risk, and reviewed the advantages 
of monitoring particle number in order to reduce residual 
risk.455 Tests for LDL-P are FDA approved and their pre-
dictive ability was confirmed in the MESA study.456 These 
statements reflect that risk is better captured by apoB or 
LDL-P than by non-HDL-C, which itself may be discor-
dant with apoB in about one-third of patients, and many 
lipidologists believe non-HDL-C is superior to LDL-C. 
It is important to note that the effect of individual statins 
upon lipid subfractions may differ,457 as may the relative 
effect upon LDL-P. In 318 patients with dyslipidemia and 
the metabolic syndrome, for instance, rosuvastatin was 
found to be superior to atorvastatin in lowering LDL-P.458 
Further discussion is available in the recent contribution 
by Dayspring et al.459
The NCEP-ATP III153 presently recommends LDL-C 
as the primary target to be monitored, but after the LDL-C 
goal is reached, and if triglyceride levels are $200 mg/dL, 
non-HDL-C is set as a secondary goal at 30 mg/dL higher 
than the LDL goal. The fourth Joint European Societies 
Guidelines31 estimates risk of fatal cardiovascular events 
using SCORE,150 which is similar to Framingham but uses 
total cholesterol/HDL-C as the primary target. The Joint 
British Societies (JBS 2) guidelines293 uses similar criteria 
and the total cholesterol/HDL-C, to estimate 10-year risk, 
but employs LDL-C treatment targets.
Using Framingham data, Liu et al460 found that VLDL-C 
was a significant predictor of cardiovascular risk, and that 
non-HDL-C was superior to LDL-C in predicting risk. In a 
large study of healthy Japanese men and women, the total 
cholesterol/HDL ratio best reflected long-term changes in 
lipid risk with the least within-person variation when com-
pared to LDL-C.460 The superiority of measuring ratios of 
pro- to anti-atherogenic lipoproteins with respect to errors 
was also supported by Glasziou et al.461 An analysis of 
INTERHEART data found that non-fasting apoB/apoA-I 
was superior to other cholesterol ratios for estimation of the 
risk of myocardial infarction for all ethnic groups, ages, and 
in both sexes.463
The causal role of elevated lipoprotein(a) [Lp(a)] in 
premature cardiovascular disease has also been of interest. 
Presently Lp(a) elevations are probably not being given 
sufficient attention, and many are missed in routine lipid Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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measurements, yet its relationship with CHD is robust and 
specific. The EAS Consensus Panel has critically reevaluated 
Lp(a) as a risk factor, and supported screening patients at 
intermediate or high CHD risk with premature CHD, familial 
hypercholesterolemia, a family history of premature CVD 
and/or elevated Lp(a), recurrent CHD despite statin treat-
ment, $3% 10-year risk of fatal CVD according to European 
guidelines, and/or $10% Framingham risk.464
In summary, LDL-C has limitations which are well 
recognized. ApoB is a better predictor than LDL-C,465 
is not generally available, and has not been embraced 
clinically. Non-HDL-C, a proxy for apoB, measures the 
cholesterol content within atherogenic lipoproteins and is 
easily derived from standard lipid profiles, but may not 
reflect the full residual risk when particle number is dis-
cordant. Non-HDL-C is incorporated in several   guidelines. 
LDL-P is the most accurate when predicting risk, is only 
available through independent laboratories, and reim-
bursement is irregular.452,466   Targets for the highest risk 
patients are LDL-C , 70 mg/dL,   non-HDL-C ,100 mg/
dL, apoB , 80 mg/dL,454 and perhaps LDL-P # 
1000–1100 nmol/L.
Risk and the significance of CRP  
and inflammation in prevention  
and pathogenesis
Epidemiological, pathological, clinical, and imaging studies 
have constructed an evolving model of atherothrombotic 
disease, spanning the period from biochemical and physical 
triggering of endothelial dysfunction to rupture of a vulner-
able plaque. Although atherothrombosis was once consid-
ered to consist of simple lipid and “plumbing” problems, a 
unifying concept of the role inflammation is now supported 
by considerable data in both the clinical and preclinical sci-
ences. The numerous beneficial anti-inflammatory pleiotropic 
actions of statins and results of the JUPITER study suggest 
inflammation matters clinically.467–472
In a number of conditions and processes, including chemi-
cal injury, hypercholesterolemia, hypertension, endothelial 
dysfunction, cytokine stimulation, oxidative stress, and others, 
trapping of chemically modified LDL occurs within the arte-
rial wall.473 Inflammatory monocyte recruitment,474 under the 
influence of cytokines and other protein mediators, leads to 
the expression of scavenger receptors for altered LDL and the 
formation of foam cells.467 C-reactive protein is a biomarker of 
inflammation, with hepatic expression driven by interleukin-6 
(IL-6), the “messenger” cytokine (notifying and activating 
the immune system after tissue injury). High CRP levels are 
closely associated not only with infections but with vascular 
disease, cancer, and autoimmunity. Evidence underpinning the 
close associations of CRP levels with vascular disease and its 
predictive value are the result of the accrual of knowledge over 
a long period of time by many investigators.15 High-sensitivity 
C-reactive protein (CRP) is able to discriminate levels of the 
protein at concentrations far below the greater variations asso-
ciated with generalized inflammation. There is evidence that 
CRP concentrations reflect aspects of inflammation related 
to lifestyle, such as visceral obesity,475,476 and the metabolic 
syndrome,477,478 lack of physical activity,479 vegetable and fruit 
consumption,480 omega-3 fatty acid ingestion,481 and alcohol 
intake,482,483 all of which may not be fully captured by other 
risk markers, such as LDL. In fact, despite great attention 
to the genetic variations influencing CRP levels, lifestyle is 
actually the more significant determinant.484 Further, CRP 
levels are associated with all 7 health behaviors and factors 
that were cited by the AHA as components of ideal cardio-
vascular health (Table 2).2
The associations among visceral adiposity, diabetes, 
metabolic syndrome and inflammatory markers,341,485,483 
as well as the relationship between the first three entities 
with elevated CRP,484 are well-known. The link between the 
metabolic syndrome and atherosclerosis involves elements 
other than insulin resistance, and CRP levels correlate with 
both the diagnosis of metabolic syndrome and the number 
of risk components.488 Adipose tissue releases IL-6 which 
stimulates CRP synthesis, but is also a significant source 
of CRP itself. Weight loss in obese women lowers CRP and 
raises adiponectin concentrations.489 CRP correlates with 
insulin levels,490 and the Mediterranean diet lowers insulin 
resistance and CRP levels.488 The Look AHEAD (Action 
for Health on Diabetes) study recently reported on a large 
cohort of overweight diabetic women whose CRP levels 
fell markedly in response to intensive lifestyle intervention 
resulting in weight loss over a 1 year period.492
While elevations of IL-6 and CRP are associated with 
illnesses that are expected to shorten life, low values, while not 
a guarantee of freedom from diabetes or CHD, may generally 
reflect better health. The Rancho Bernardo Study493 found 
that higher concentrations of these inflammatory markers 
predicted shorter survival time and reduced lifespan among 
older men. In addition, in various clinical situations, CRP 
levels correlate with mortality494,495 and survival,496 with strong 
predictive ability in many cardiovascular scenarios.497–503 In 
the Emerging Risk Factors Collaboration,497 a meta-analysis 
of 54 prospective studies, CRP correlated better with future 
vascular events than either blood pressure or cholesterol. Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Although the prognostic value of CRP in a broad population 
of patients at high risk for ischemic events is accepted, clinical 
utility of using CRP in treatment remains debated.504
CRP, as a pattern recognition molecule capable of 
activating complement, functions as a regulator in the 
innate immune system, the latter increasingly recognized as 
a participant in atherosclerosis.471,472,474,505,506 Oxidized LDL 
and oxidized phospholipids on surfaces of apoptotic cells 
are recognized by macrophage scavenger receptors, have 
proinflammatory and proatherogenic properties,507 and CRP 
binds to both through recognition of the phosphorylcholine 
moiety in oxidized phospholipids.508 The innate immune 
system appears to prime normal protective T cell-mediated 
immunity,509 which is involved in the inflammation associated 
with the metabolic syndrome510 and hypertension,511 two 
conditions in which CRP levels are frequently elevated. 
Clinically, the involvement of inflammation may explain 
the correlation of CRP elevations and early atherosclerosis 
detected by CIMT.512,513
In addition to inducing release of proinflammatory 
cytokines from monocytes, upregulating NADPH oxidase 
activity, and promoting endothelial dysfunction, CRP appears 
to have a role in priming differentiation of human monocytes 
toward a proinflammatory M1 phenotype, a critical event in 
the pathogenesis of atherosclerosis. Transformation of mono-
cytes, or M1 polarization, may be regarded as an on-off switch 
in the balance between pro- and anti-inflammatory processes, 
and lead to macrophage maturation, further expression of 
inflammatory cytokines, and tissue destruction. Macrophage 
infiltration of adipose tissue in obese animal models and 
humans is associated with both an absolute rise in the number 
of M1 polarized macrophages and reduced sensitivity to insu-
lin. M1 monocytes also infiltrate atherosclerotic lesions.
Recognition of modified extracellular matrix proteins by 
the innate immune system results in collateral blood vessel 
remodeling to accept additional blood flow. The encounter 
of agonists and toll-like receptors (TLR), another class of 
pattern recognition receptors, specifically TLR2 and TLR4 
on monocytes and extracellular matrix fragments, leads to 
inflammation through the activation of the nuclear factor 
kappa B and interferon response factor pathways, in turn 
increasing the expression of proinflammatory cytokines, 
chemokines, matrix metalloproteinases, interferons, growth 
factors, and other molecules involved in arteriogenesis. 
There is a dynamic interaction between reduced blood flow, 
modified extracellular matrix proteins, and collateral vessel 
growth/vascular remodeling, in which TLR, monocytes and 
T-lymphocytes are involved.514,515
The recent recognition of the important and extensive role 
of the innate immune system in arteriogenesis, the increase 
in diameter of preexisting arteriolar connections, arterial 
remodeling during ischemia and atherosclerosis adds yet 
another dimension to pathogenesis of the disease.516 The full 
role of this process as a mechanism which protects against 
ischemic injury has yet to be determined.
Strategies proposed to improve 
cardiovascular risk reduction
The concept of risk factors, introduced by the original 
Framingham investigators in 1961, essentially established 
preventive cardiology. Risk factors are now accepted 
antecedents of atherosclerosis whose levels predict sub-
sequent cardiovascular events and are targets for therapy. 
The current approach to cardiovascular risk screening 
is summarized in a state-of-the-art paper by Berger and 
associates.52
Within the past few years there has been a reevaluation 
of reducing risk in the general population, and the central 
unanswered question is: how can people who will eventu-
ally have cardiovascular events be identified and their risk 
lowered? There is no ideal or “gold-standard” risk equation 
for assessment, nor a drug-response equation for treatment. 
Current issues in primary prevention of CHD include the long 
incubation period; methods of evaluating risk in the popula-
tion; population-based vs individual risk-based approaches; 
role and refinement of global risk factor scores; choice and 
merits of nontraditional risk factors; multiple biomarker pan-
els; imaging techniques in evaluation and ongoing therapy; 
value of advanced lipid testing; weights given to traditional 
risk factors, cutoff values and treatment targets, particularly 
LDL goals in guidelines; use of statins in primary preven-
tion; reasons for low patient adherence with evidence-based 
therapies; causes of “clinical inertia” and lack of physician 
compliance with guidelines; and the etiologies, extent, and 
minimization of residual risk. Within this period, there have 
been several suggestions based upon models, proposals, and 
clinical protocols contributing to the dialog, enumerated 
below with additional commentary.
encourage population-based 
interventions emphasizing primordial 
prevention
Primordial prevention is the unchallenged method of choice 
for risk reduction, far more efficient than pharmacological 
intervention. A long tradition of epidemiological data has 
accumulated since the pioneering report of de Lorgeril Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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et al concerning the Mediterranean diet517 and the Lyon 
Diet Heart Study.518 About that same time, Stamler and 
coworkers519 published a series of 2 cohorts totaling 366,000 
participants and reported that just 4 favorable risk factors 
(BP , 120/80 mm Hg, TC , 200 mg/dL, abstinence from 
tobacco, and no diabetes) was associated with a 72%–92% 
lowered cardiovascular mortality and an additional 5.8–9.5 
years of life. Since then, there have been a great number 
of ongoing investigations and exceptional contributions 
affirming the favorable impact of the Mediterranean diet 
pattern and physical activity upon all-cause longevity, car-
diometabolic, and other chronic diseases.520–523 The evidence 
supporting the effectiveness of lifestyle modification upon 
cardiovascular outcomes is summarized elsewhere2,11 and 
continues to amass.40,524
While primordial prevention is most desireable,177,525 
social and political barriers are considerable, and current 
individual resistance to major behavioral modification is 
complex and not well understood. Perhaps the milieu of 
modern life has de-emphasized personal responsibility – or 
made it so difficult – for so long that the public now dismisses 
attempts to reverse these concepts as impractical, imposing, 
irrelevant, or unworthy. The message that medical care is 
unlimited and uniformly successful at all stages of disease 
may also unwittingly reduce motivation for personal health 
ownership. It would therefore appear that public re-education 
is fundamental for further progress, rather than a wasteful 
endeavor.
At the same time, it has been suggested that continued 
attempts to reduce cardiovascular risk without the   addition 
of population-wide prevention is destined to fail.526 Plainly, 
furnishing entire populations with unlimited scans, statins, 
stents, and surgery is not the best answer. For this   reason, and 
because it is premature to declare risk reduction   programs a 
failure without further data or better alternatives, interest in 
refining and continuing comprehensive primordial prevention, 
including education and counseling, continues. A combined, 
multipronged, intensive approach to cardiovascular risk 
reduction using many techniques will be necessary.
Change the lipoprotein or lipid fraction 
that is monitored and targeted
As discussed above, non-HDL-C measures all atherogenic 
lipoproteins which contain apolipoprotein B, includ-
ing LDL-C, very low-density lipoprotein cholesterol 
(VLDL-C), intermediate-density lipoprotein cholesterol 
(IDL-C), lipoprotein(a), chylomicrons, and chylomicron 
remnants. Non-HDL-C provides a more complete measure 
of atherogenic particles than LDL-C and is believed to be 
superior in capturing residual risk and ability to predict car-
diovascular events. Evidence now indicates that monitoring 
and targeting non-HDL-C can better predict cardiovascular 
events than use of LDL-C,326,446,527,528 with up to twice the 
yield.529 Advanced lipid testing may identify abnormalities 
in small, dense LDL particles, LDL-P, HDL2[b], and Lp(a) 
fractions in a surprising number of patients. Ideally, all lipid 
pathology should be addressed to minimize cardiovascular 
events.
Use “lifetime risk” rather than global 
10-year risk scores, and start treatment 
much earlier
Estimates of lifetime risk assessment offer an important 
tool which may be used in conjunction with 10-year risk. 
With 56% of American adults scoring a low 10-year, but 
a high lifetime risk, this issue has received increasing 
consideration.213 The difference becomes of particular 
  concern in both young and asymptomatic people.185,530 
Lifetime risk may be estimated after Lloyd-Jones27 or as a 
30-year Framingham risk that accounts for competing risks.531 
In the JUPITER study of rosuvastatin in primary prevention, 
about half of the participants had a 10-year FRS , 10%, 
but a significant number benefited when their LDL-C was 
lowered from a mean of 108 mg/dL to a mean treated value 
of 55 mg/dL, reflecting the degree of unrecognized cardio-
vascular risk in an asymptomatic population.532
Using lifetime risk, beginning treatment early, and con-
tinuing therapy over an extended period, matches the timing 
of treatment to the time of disease progression, which is 
amply supported by newer data concerning pathogenesis of 
the disease.
Give statins to intermediate-risk 
individuals guided by CRP – dual targeting 
using JUPiTeR criteria
The JUPITER study532 involved 17,802 individuals with 
LDL , 130 mg/dL and CRP $ 2 mg/L, free from diagnosed 
cardiovascular disease or diabetes, and included women, 
minorities, and the elderly. The mean LDL-C was ≈100 mg/dL, 
and the average FRS was 11.6%.   Treatment with rosuvastatin 
20 mg, compared to placebo, was associated with a statisti-
cally significant 54% reduction in myocardial infarction, a 
47% reduction in need for angioplasty or bypass surgery, a 
48% reduction in stroke, a 43% reduction in venous throm-
bosis, and a 20% reduction in all-cause mortality. The JUPI-
TER study group concluded that primary prevention patients Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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with high CRP values were at greater risk despite acceptable 
LDL-C levels and low Framingham Risk Scores, and such 
individuals benefited from rosuvastatin therapy. The 5-year 
number to treat was 25, which compared favorably with other 
primary prevention methods, such as hypertension.
JUPITER definitively established the efficacy of 
rosuvastatin in primary prevention.532 The controversy sur-
rounding the JUPITER trial is discussed elsewhere.15 Pro-
ponents and critics agree that the benefits of rosuvastatin in 
JUPITER-eligible participants, however, were real. The US 
Food and Drug Administration approved new indications 
for rosuvastatin to include asymptomatic JUPITER-eligible 
individuals with 1 additional risk factor. The Canadian 
Cardiovascular Society guidelines recommend testing for 
CRP, and using statins in persons with low LDL-C and 
high CRP levels at intermediate risk. The joint European 
Society of Hypertension/European Society of Cardiology 
Guidelines suggested CRP measurements be included in 
the assessment of risk in hypertensive patients.533 In a recent 
post hoc analysis of JUPITER requested by European health 
authorities,534 patients with an estimated SCORE risk $ 5% 
or FRS score . 20% had significant reductions of 43%–53% 
reduction in the risk of MI, stroke, or cardiovascular death 
when treated with rosuvastatin, compared with those treated 
with placebo. SCORE, as noted above, does not include CRP 
measurements. In their decision, the European Medicines 
Agency compromised between scientific evidence and eco-
nomics, and their extension for rosuvastatin use in high-risk 
patients was admittedly arbitrary.
A recent reanalysis535 of cost-effectiveness demonstrated 
that rosuvastatin in JUPITER-eligible patients had an incre-
mental cost-effectiveness of $25,198 per quality-adjusted 
life year (QALY) gained compared to customary care. 
When applied only to patients with an FRS $ 10%, the 
incremental cost-effectiveness became $14,205 per QALY. 
Unknowns with respect to long-term effects cloud the issue, 
since sustained effects are assumed, but data is lacking.536 
All proposals to improve risk refinement and lower risk 
burden, even nonselective administration of generic statins, 
will incurr expense.
The continuing debate about the use of statins in primary 
prevention, while quite apart from the JUPITER trial, has been 
connected to JUPITER for unclear reasons.15 Whenever use 
of statins in primary prevention is discussed, the cholesterol 
hypothesis, saturated fat-cholesterol link, JUPITER, and side 
effects of statins are also commonly argued de novo. Often in 
blogs and nonacademic publications the information presented 
is not evidence-based, but internet-based. Some authors have 
asserted that three-fourths of patients who take statin drugs 
for primary prevention – a significant number of all who 
use statins – do not benefit.292,537 Several guidelines from the 
American College of Cardiology, American Heart Associa-
tion, and European Society of Cardiology disagree with this 
view. It has also been said that the JUPITER study masked or 
caused a loss of appreciation for primordial prevention23,24 but 
the debate concerning statin effectiveness in primary preven-
tion predated the publication of JUPITER and is ongoing.36,298 
No responsible cardiologist questions the value of primordial 
prevention before pharmacologic therapy. Individuals fol-
lowing a Mediterranean or Paleolithic diet who achieve ideal 
cardiovascular prevention would not need any therapy.538 The 
reality is that adherence to the Mediterranean diet, or any 
other lifestyle leading to ideal cardiovascular health, has fallen 
markedly even in areas of traditional origin – the Greek Islands 
– in favor of Western fare, accompanied by a corresponding 
increase in risk for CHD. Reversing this deterioration is the 
unmet challenge. The continuing fall in ideal cardiovascular 
health associated with poor lifestyle choices and the dual 
epidemics of obesity and diabetes are unrelated to the avail-
ability of statins or any particular application.
When lifestyle modification fails in individuals who 
are JUPITER-eligible, with “normal” LDL-C and high 
CRP levels, clinicians have an additional choice of using 
rosuvastatin to improve outcomes. This approach is simple, 
noninvasive, easily repeated, and does not involve radiation. 
CRP has been found useful in reclassifying risk in several 
series including the Framingham Heart Study, the Women’s 
Health Study, the Physicians’ Health Study, the Uppsala 
Longitudinal Study of Adult Men, the MONICA-Augsberg 
cohort, the EPIC Norfolk study, the Atherosclerosis Risk 
in Communities study, and the Heart and Soul cohort. The 
2010 ACCF/AHA Guideline for Assessment of Cardiovascu-
lar Risk in Asymptomatic Adults,32 concluded that measuring 
CRP levels in JUPITER-eligible patients can be useful in 
the selection of patients for statin therapy, ie, that beginning 
statins in this population is reasonable, with recommendation 
Class IIa, Level of Evidence (LOE) of B.
increase utilization of imaging:  
CiMT and CAC
Carotid intima-media thickness (CiMT)
CIMT is a useful, noninvasive, inexpensive, reproducible but 
operator-dependent, predictive, radiation-free, office-based 
technique.539–542 An increase in CIMT predicts the risk of 
cardiovascular events, but associations with cerebral arteriial 
events are stronger than with coronary events, relating more Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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to variability and differences in atherosclerosis between 
the two arterial beds than to limitations in CIMT measure-
ments. CIMT also provides information about noncalcified 
plaque.543 CIMT may detect significant atherosclerosis in 
patients with a zero calcium score, more likely to be young 
and/or female. Of 89 patients with a CAC of 0, mean age 
48 years, CIMT found evidence of carotid atherosclerosis 
in 42 (47%; 95% CI: 37%–58%).544 CIMT may be more 
sensitive than CAC in detecting subclinical atherosclerosis 
in a younger population, when treatment would produce 
greater benefits over time. It is believed that since calcifica-
tion occurs later in the natural history of the disease, earlier 
stages of atherosclerosis – vulnerable plaque and noncalcified 
“inflammatory” lesions – may be found by CIMT. Therefore, 
CIMT may also find particular application in young healthy 
individuals, as well as in women and black patients.545 Once 
detected, however, coronary calcium is a much more powerful 
predictor of future coronary events than CIMT.219
CIMT has also been used effectively to monitor disease 
progression in individual patients, and in studies comparing 
properties of subgroups within a given diagnosis. In diabetes, 
for instance, CIMT has contributed to the understanding of 
vascular disease in people with normal glucose tolerance, 
impaired tolerance, overt diabetes, in those with hypertension, 
microvascular and other complications, and after treatment 
with hypoglycemic, antihypertensive, lipid-lowering and 
anti-platelet agents.546 As mentioned above, CIMT may be 
more appropriate as a surrogate in some populations and less 
adequate in others.547 Since the intima may thicken, and the 
media may become hypertrophic with age, not all elevations 
in CIMT in the elderly are due to atheroma.
Despite widespread use of CIMT serially to assess effects 
of therapeutic agents, a recent meta-analysis suggests limited 
usefulness for this purpose. Costanzo et al548 undertook a 
weighted random-effects meta-regression analysis to test 
mean and maximum CIMT changes and hard outcomes. 
They included 41 trials totaling 18,307 participants. Despite 
significant reductions in CHD and CVD events, as well as 
in all-cause mortality induced by various interventions, they 
found no significant relationship between CIMT regression 
and events in any of these categories. The surprising 
conclusion was that neither regression nor progression of 
CIMT changes correlated with, or predicted, changes in 
major cardiovascular events associated with various drug 
treatments in patients at intermediate to high cardiovascular 
risk. These findings, which disagree with the bulk of prior 
experience, may be due to limitations of the meta-regression 
analytic method and the limited length of follow-up in the 
component studies. Replication of the data and explanation 
of inconsistencies are required.
Nonetheless, CIMT provides an excellent risk prediction 
tool which may be repeated easily. In the past 10 years, seven 
guidelines or consensus statements have recommended using 
CIMT or carotid plaque detection to predict risk.549 The 
USPSTF was not one of them.550 Among several potential 
applications of CIMT, appropriate use criteria rated seven as 
appropriate, 16 as uncertain, and 10 as inappropriate.364
The 2010 ACCF/AHA Guidelines for Assessment of 
Cardiovascular Risk in Asymptomatic Adults32 have assigned 
a Class IIa, LOE B recommendation for CIMT for risk assess-
ment in asymptomatic individuals in the FRS intermediate risk 
category. Additional mention was made that recommendations 
for equipment, technical approach, operator training and expe-
rience for performance of the test must be followed. Some 
characteristics of CIMT and CAC are compared in Table 8.
Coronary Artery Calcium scoring (CAC)
Together with traditional risk factors, CAC also increases 
discrimination between patients who will or will not 
have future events, and improves prediction.551,552 CAC is 
noninvasive, sensitive, automated, involves radiation exposure 
(0.7–1.8 mSv depending upon method), and is somewhat more 
expensive per test than CIMT, requiring greater operating costs 
and a much larger capital outlay. A great deal of data and a 
number of reviews have recently been published concerning 
Table 8 Characteristics of CiMT and CAC by CT
Quality of interest CIMT  
(Ultrasound)
CAC scoring  
(CT)
Area intima-media Calcified lesions
Radiation None 0.7 mSv for eBT   
and 3–5 mSv for   
helical CAC  
(may vary  
10-fold up to  
10.5 mSv)
Sensitivity 50 to 70 85
Specificity 60 to 80 75
Hazard ratio for incident  
CvD event per SD  
increment change title
1.3 2.1
Reclassification improvement Unknown Yes
Discrimination improvement Uncertain Yes
Operation simplicity ++ +++
Operation reproducibility User dependent Automated
Approximate cost US $200 US $300–$600
Capitalization and access Low-within office  
and research access
High-larger  
facility access
Abbreviations: CAC, coronary artery calcium; CT, computed tomography; CiMT, 
carotid intima-media thickness; eBT, electron beam tomography.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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the potential of CAC.193–195,553–562 Special note should be made 
of the Society for Heart Attack Prevention and Eradication 
(SHAPE) guideline,560 advocating early use of CAC in primary 
prevention patients 563,564 with updated commentary.553
Nasir et al,565 reporting on of 1,611 asymptomatic indi-
viduals (67% men, mean age: 53 ± 10 years) who had CAC 
scores performed using single electron beam tomography, 
found that 59% of those with a CAC score .400 and 73% 
with a score .75th percentile would not have been eligible 
for statins using NCEP ATP III criteria. CAC scores were 
able to reclassify 55% of patients classified as FRS-low 
risk to an intermediate risk category, and 45% of those with 
intermediate risk to high risk. In terms of biological age, 
linear prediction models showed that a CAC score ,10 led 
to a reduction in observed age of 10 years in asymptomatic 
individuals over age 70, compared to those with a CAC 
score .400, which added up to 30 years of biological age 
to younger patients.566 Hence, a CAC of 0 has been called a 
“priceless” possession.567
A patient with some calcium has a relative risk $ 2 com-
pared with a CAC of zero, and in those with a CAC . 100, 
the relative risk is .4. The greatest value of CAC scoring is 
in patients classified in the FRS intermediate risk group. The 
reclassification rate is 54%, with 16% moving into the high 
risk category. In the Rotterdam study,556 the relative risk of a 
CHD event between the highest 11% and the lowest 50% of 
the calcification score distribution was 8.3. For individuals with 
a CAC of zero, the practitioner may be more inclined to avoid 
statins and aspirin, given their finite complication rates. A 
CAC over 100 might suggest aggressive LDL-C lowering with 
continuation of aspirin. For very high CAC values, over the 
75th percentile for age and gender, vigorous medical therapy 
is indicated with further work-up according to guidelines.
The MESA study219 found the association between 
incident cardiovascular events stronger with CAC than with 
CIMT (hazard ratio for incident event per SD increment 2.1 
and 1.3 respectively), and an area under the receiver operating 
characteristic curve of 0.81 and 0.78. While a popular sub-
ject for debate has been the relative advantages of CAC and 
CIMT for risk stratification in primary prevention,568 these 
techniques, as well as CRP measurement, are complementary 
clinical tools, rather than competitors.
For detection of plaque regression, CAC may not be 
reliable. Some reservations have also been voiced about the 
clinical usefulness and cumulative radiation exposure in 
heart patients.199,224,568–579,633 While the radiation exposure per 
procedure is now lower with new technology, exposure is 
uneven. Cumulative radiation exposure in adults, even in 
children, is rising, since imaging for all purposes is becoming 
common.580–582 In view of the long delay between exposure 
to ionizing radiation and development of cancer, as well as 
its certainty, researchers have suggested that enthusiasm for 
cardiac imaging should be tempered.579
Another potential distraction is the finding of “incidenta-
lomas” on imaging – about 20%–53% of electron-beam CT 
and 15%–67% of multidetector row CT report extracardiac 
lesions. About 5%–11% are significant, with 4%–25% of them 
potentially significant.583 Additional tests, expense, inconve-
nience, professional time, and patient anxiety may follow. 
The US Preventive Services Task Force (USPSTF) disfavors 
CAC because it leads to additional testing and may funnel 
asymptomatic individuals to catheterization laboratories. In 
contrast, advocates cite some tests and revascularizations 
that may also be avoided. When patients are found to have a 
zero calcium score, less aggressive LDL-C targets translate 
into less expensive protocols with generic statins, but the 
quantitative significance of this remains uncertain.
An intriguing study from Johns Hopkins School of 
Medicine reported on the use of CAC in 950 healthy male 
and female participants with LDL-C , 130 mg/mL and 
CRP $ 2 mg/L from the MESA population over a 6-year 
period.221 About 47% had a calcium score of 0, 28% had a 
calcium score of 1 to 100, and 25% were in a high-risk group 
with a calcium score over 100. About 75% of the deaths 
related to CVD events occurred in the highest-risk group. 
According to these data, in individuals with a calcium score 
of 0, the CHD event rate was 0.8 per 1000 patient-years, the 
number needed to treat (NNT) to prevent one CHD event was 
549, and for a CVD event, NNT was 124. In the group with 
a score between 1 and 100, the event rate was 4.8 per 1000 
patient-years. In the group with CAC . 100, the CHD event 
rate was 20.2 per 1000 patient-years, and the NNT to prevent 
1 CHD event was 24, and for 1 CVD event, 19. The hazard 
ratio for a CHD event in the highest-risk group of 24.8 (95% 
CI 2.5–14.6) is indeed convincing. Placing this information 
in perspective will require further randomized trials. These 
data clearly show that a significant amount of cardiovascular 
risk and incipient pathology exists within the asymptomatic, 
nondyslipidemic population who do not presently qualify for 
further medical attention. More patients are now presenting 
with LDL-C values that are not especially elevated, which may 
elicit undertreatment with statins (see above discussion).
The use of CAC as a noninvasive test for risk stratification 
of emergency department (ED) patients with chest pain in order 
to decide whether to proceed with coronary angiography or 
discharge is a different, although similarly controversial, Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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issue than stratification of asymptomatic individuals classified 
as intermediate risk using FRS. Sarwar and colleagues584 
reported data from 18 studies that revealed any CAC had a 
pooled sensitivity and negative predictive value of 98% and 
93%, respectively, for finding significant CHD on invasive 
coronary angiography. Even so, Garcia and Fuster585 noted 
that from those same data, while the incidence of obstructive 
CHD in chest pain patients with zero CAC scores is small, at 
7.2% it is not negligible. Candemartiri et al586 found that CAC 
scoring was inadequate when compared to computed tomog-
raphy coronary angiography (CTCA) in excluding CHD in 
asymptomatic, high-risk patients. Gottlieb et al587 reported 
that the absence of coronary calcification (CTCA) had a posi-
tive predictive value of 81%, and a lower negative predictive 
value of CAC of 68%, and therefore a zero CAC score does 
not reliably rule out significant CHD in patients being referred 
for coronary arteriography. Of those, about 20% had a high 
pretest probability of CHD, 75% had an intermediate, and 5% 
had a low probability of CHD. In an accompanying editorial, 
Redberg588 commented the practice should be discouraged, 
largely due to the failure to predict 19% of patients with CHD 
as well as a finite radiation risk. While the radiation for CAC 
is minimal, with a median value of ≈3 mSv, roughly equal 
to that of a mammogram or 100 chest x-rays, the variation 
is considerable (2–7 mSv),224 and multiple scans in the same 
patient are becoming more common. Generally, patients’ 
perceptions of cumulative CT radiation risk are inaccurate.589 
Three years ago, the number of future malignancies from CT 
scans done in 2007 was estimated at ≈29,000, corresponding 
to some 15,000 deaths.590 In contrast, supporters argue that 
CAC scores are of immense help in evaluating chest pain in 
the ED and elsewhere.195,233,567,592–594
A summary of the utility of CAC in risk evaluation594 con-
cludes, as do guideline writers, that the absence of detectable 
coronary calcium is associated with a favorable prognosis, 
but is imperfect and carries a limited (92%) warranty of about 
4.1 ± 0.9 years.223 While CAC measurement does refine risk 
stratification above that provided by the FRS in asymptom-
atic, intermediate-risk patients, whether doing CAC scoring 
earlier in more patients will result in improved long-term 
clinical outcomes has yet to be decided, and doing so will be 
difficult. Restricting use based upon lack of such data may be 
too stringent a requirement. A larger question is whether CAC 
used to assess higher risk is superior to a population based 
strategy. In response to correspondence regarding the role of 
CAC scoring, Redberg595 opined that, despite two decades of 
study, data showing patient benefits from information derived 
from the CAC are still lacking, and that for this reason, the 
USPSTF concluded the evidence regarding CAC score is 
insufficient to assess the benefit to risk ratio.550
Baseline measurements of CAC have received a Class IIa, 
LOE B recommendation (reasonable) for those at intermediate 
(10%–20% 10-year) risk or Class IIb for individuals at low 
to intermediate risk by the 2010 ACCF/AHA Guidelines for 
Assessment of Cardiovascular Risk in Asymptomatic Adults, 
and for those at low to intermediate (7%–10% 10-year) risk, 
a Class IIb, LOE B recommendation.32 No recommendations 
have been made for CAC progression for assessing treatment. 
CAC progression may provide even more valuable informa-
tion, but also requires sequential CT scans with additional 
radiation exposure, together with other limitations.596
Allocate statins to low- and intermediate-
risk individuals using specified risk 
thresholds, rather than ATP iii or 
JUPiTeR criteria
There is some evidence that extending statin therapy to 
Framingham low- and intermediate-risk individuals may be 
cost-effective at all levels of LDL-C.316,597,598   Reservations 
about such a policy arise from potential side effects and 
expense. As was done in JUPITER, a CRP $ 2.0 mg/L 
can be used to identify those persons with higher risk in 
a population without ATP III-defined dyslipidemia who 
might benefit from statin therapy. A different approach to 
efficient lowering of cardiovascular risk was suggested by 
Lee et al.302 These investigators examined the cost effective-
ness of strategies following three hypothetical cohorts of 
individuals starting at age 40 with normal lipid levels and 
no diagnosed coronary artery disease, peripheral arterial 
disease, or diabetes. Their Markov decision analytic model 
compared three situations using: a) ATP III guidelines, a cur-
rent popular strategy; b) CRP screening in JUPITER-eligible 
patients, followed by statin treatment only for those with 
CRP elevations, as suggested by the JUPITER study; and 
c) a strategy of starting statin therapy at specified predicted 
risk thresholds without first performing any CRP testing. 
Assuming that the relative risk reduction in events by statins 
is uniform whatever the baseline risk might be (statins are 
equally effective regardless of CRP status, providing ben-
efits in low-risk individuals with normal LDL-C and CRP 
levels) the most cost-effective strategy was c). Thus, treating 
individuals at significantly lower risk than those currently 
being treated without using CRP screening was favored by 
these authors. However, if a normal CRP level meant that 
little or no benefit would result from statins, than strategy Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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b), treating the dual targets of LDL-C and CRP, would be the 
most cost-effective strategy. Notably, however, this analysis 
did in fact show that CRP testing is superior to current ATP 
III guidelines for individuals at “intermediate” FRS risk.
Other assumptions in this study were that statins 
remained inexpensive (generic simvastatin was used for 
their calculations), 17.5% of participants would discontinue 
statins within 6 months due to intolerance, rhabdomyolysis 
and renal failure would occur in 5–30 patients per 1 million 
treated with statins, and there were no long-term adverse 
effects of statins. If patient adherence to statin drugs was 
in fact poorer for any reason,90 the calculations for cost-
effectiveness would become invalid. In fact, the lead author 
of the paper remarked in a subsequent interview that “it 
doesn’t take much to make statins not cost-effective for such 
large-scale use”.
In their equal-effects scenario, it was assumed relative 
risk reductions from statins were not a function of FRS or 
CRP levels, and that statin therapy lowered the risk of MI 
by a factor of 0.77, and the risk of stroke by a factor of 0.83. 
In the differential scenario, it was assumed that individuals 
with high CRP values modified statin effectiveness, with 
relative risks of 0.46 for MI and 0.52 for stroke (data from 
JUPITER). An interactive presentation of the model with 
variable risk factors is accessible at http://med.stanford.edu/
hsr/crp-screening.
The assumption of uniformity of effectiveness of all 
statins for all individuals, across ethnic and other groups, 
regardless of LDL-C, HDL-C, lipid subfractions, CRP and 
other biomarkers should be noted. If a normal CRP could 
exclude effectiveness of statins, then CRP-guided therapy 
would be best. According to the authors, because JUPITER 
did not have a normal LDL-C/normal CRP group for com-
parison, it remains unknown whether CRP elevations merely 
increases risk, or a normal CRP indicates ineffectiveness of 
statins in such a low/normal-CRP cohort. However, even 
though JUPITER did not have such an arm, data from other 
sources suggest that CRP does have discriminatory   capability. 
In the AFCAPS/TexCAPS study, the relative risk reductions 
associated with the use of statins in patients with high CRP 
values was 42%, higher but not significant compared to the 
lower risk reductions in patients with normal CRP levels.599 
A subanalysis of JUPITER did demonstrate a relationship 
between outcomes in rosuvastatin-treated individuals and 
CRP levels.279
There was no consideration for any differential in effi-
cacy, side effects, or potential interactions between rosuvas-
tatin and simvastatin, but these potential differences may 
become important clinically. Simvastatin, as a highly lipo-
philic statin, is associated with a higher incidence of both 
myopathy and other adverse reactions than rosuvastatin, 
which is hydrophilic.15 Further, since simvastatin is 
metabolized through the CYP3A4 enzyme, the probability 
of interactions with coadministered CYP3A4 substrates, 
inhibitors and inducers is much greater than with rosuvas-
tatin, and package inserts by manufacturers reflect these 
data. For instance, simvastatin dosage is restricted when 
coadministered with with amiodarone and verapamil due 
to such interactions. Since polypharmacy is increasingly 
common, this may be a consideration in such a public 
health proposal.
In conclusion, if all the assumptions were true, then 
giving simvastatin 80 mg daily to all men who have no risk 
factors, without CRP testing, beginning at age 55, would 
be cost-effective, defined as less than $50,000 per quality-
adjusted life-year (QALY). For men with one risk factor, eg, 
hypertension, simvastatin would be cost-effective beginning 
at age 50, and with 2 risk factors, at age 40. Data generated 
by this model provides some insight into possibilities in lieu 
of a large, costly, long-term clinical trial.600
Allocate statins using a risk-based, 
“tailored” strategy, rather than a standard 
or intensive ATP iii treat-to-target 
approach
Five years ago Hayward et al601 questioned whether treating to 
different LDL-C targets was actually evidence-based. These 
investigators reviewed controlled trials, cohort studies, and 
case-control studies that examined the relationship between 
lowering cholesterol levels and cardiovascular outcomes in 
patients with LDL-C , 3.36 mmol/L (,130 mg/dL). There 
was no support for the premise that the response of LDL-C to 
statins predicted the degree of cardiovascular risk reduction. 
It was concluded that patients with high risk should be treated 
with statins regardless of their initial LDL-C level.
Drawing from NHANES data (1977–1994), using the 
FRS, and employing a simulated model of population-level 
lifetime effects of 5 years of treatment with statin drugs, 
Hayward and coworkers598 compared two treatment strategies. 
They chose either a conventional approach, using escalating 
treat-to-target NCEP-ATP III guidelines (in standard and 
more intensive options), or a risk-based approach (patients 
with 5%–15% CHD risk receiving 40 mg simvastatin daily, 
and those with .15% CHD risk receiving 40 mg atorvastatin 
daily). Participants were 30–70 years of age without a history 
of myocardial infarction. The investigators found that ≈70% Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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of patients would be treated similarly using the two strategies, 
14% would be treated more aggressively using the risk-based 
approach, and 17% would receive more aggressive therapy 
following the treat-to-target protocol. Intensive treat-to-target 
treatment resulted in 15 million more people being treated and 
saved 570,000 more quality-adjusted life-years over the 5-year 
period. The tailored risk-based strategy resulted in just as many 
people being treated as intensive treat-to-target therapy, saved 
520,000 more quality-adjusted life-years, but did not require 
as many patients to take high potency statins. More CHD 
events were prevented with the risk-based approach compared 
with the treat-to-target strategy, with rates of 62 and 15 per 
1000 treated patients respectively. The treat-to-target strategy 
resulted in treatment of more patients with higher LDL-C 
levels, but with lower CHD risk, whereas the risk-based 
approach caused treatment of a greater number of patients 
with elevated CHD risk, but with lower LDL-C levels.
Using the risk-based approach incorporates the log-linear 
association between lowering LDL-C and CHD risk, which 
is maintained at lower values of LDL-C. The strategy also 
addresses the population-wide underutilization of statins 
in general.602 In addition, the risk-based approach does not 
require monitoring of LDL-C, fewer physician encounters 
would be involved, and provides a simple prevention plan, 
eliminating guideline and treatment confusion among clini-
cians. Despite these advantages, and even if validated using 
a randomized trial, physician and patient acceptance would 
be difficult.
In countries where individualized care is not yet 
traditional and budgetary constraints are primary, a tai-
lored population-based approach to achieve the most risk 
reduction will be well received. At each risk level, for 
cost-effectiveness, two people taking low-dose simvasta-
tin provides better returns than one taking atorvastatin or 
rosuvastatin. Variations on this tailored treatment theme 
can be used to manage resources in optimizing population 
benefits with different statin schedules.603,604 In actual prac-
tice with higher risk patients, the reduction in events may 
still be too low. Many cardiologists believe that limiting 
therapy to statins alone, the only class of agents for which 
significant evidence exists for hard-outcome efficacy,605 
will not result in lowering events by 50%, particularly 
using simvastatin.
Limitations in the use of surrogate biomarkers rather 
than patient outcomes in the treatment of dyslipidemia were 
discussed by Krumholz and Hayward.606 Treating risk factors 
is a time-honored technique that has provided mechanistic 
understanding of the pathogenesis of atherothrombotic 
disease, and is endorsed by the FDA. From a systems 
biology point of view, however, these authors observe that 
understanding mechanisms does not necessarily lead to 
improved patient outcomes. They note that a) statins lower 
risk of MACE, revascularization and stroke,233,291 quite apart 
from the baseline lipid level; b) there is little or no evidence 
that combination therapy to achieve lipid targets actually 
improves patient outcomes; and c) the strategy used is 
more important than the change in cholesterol. To be sure, 
examples include the failures when torcetrapib, estrogen, 
clofibrate, and dextrothyroxine were used to lower cholesterol 
levels without reducing risk, and the absence of adequate 
evidence to support improvement in MACE associated with 
use of ezetimibe.
In the UK, because there are no data directly comparing 
high and low intensity statin therapy in primary prevention, 
treatment is conservative, using a “systematic rather than 
opportunistic” risk assessment, and simvastatin 40 mg is 
prescribed for individuals with a 10-year risk of 10%–20%. 
Titration to LDL-C targets and lipid and other monitoring 
is deemed unnecessary, and offering additional anti-lipid 
therapy is not routinely advised.283,285,301,607
With all proposals to lower cardiovascular risk, poor 
adherence is frequently the elephant in the room. As Rose47 
pointed out, a disadvantage of population- vs individual-based 
prevention is the small perceived benefit to the individual. 
When patients insist upon seeing objective improvement in 
their own risk factors as a requirement to continue taking 
simvastatin, adherence tends to wane.
Redefine the “normal” LDL-C level  
and eliminate multiple LDL-C goals
Defining normal LDL-C values based upon a Gaussian distri-
bution in “asymptomatic” individuals repeats intrinsic errors 
because symptomatology is a poor index of either the activity 
or stage of atherosclerotic disease. The asymptomatic popu-
lation is heterogeneous as far as cardiovascular risk, current 
pathology, and future events, and may not be “normal”. The 
mean untreated adult LDL cholesterol value is ≈130 mg/dL 
(≈3.4 mmol/L) in the USA, but lowering LDL-C levels to 
100 mg/dL–130 mg/dL only prevents 25%–35% of events, 
with symptoms frequently dissociated from pathology. 
  Evidence from contemporary hunter-gatherer societies and 
from wild primates suggests that humans are genetically 
better matched with “physiological” levels of LDL-C that 
may be on the order of 35 mg/dL–50 mg/dL.608 Indeed, 
extrapolation of data from several meta-analyses indicate that 
in primary prevention, cardiovascular events would nearly be Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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eliminated at LDL-C , 60 mg/dL. In secondary prevention 
the corresponding threshold would be LDL-C , 30 mg/Dl.607 
Humans are distinguished by uniquely elevated LDL-C val-
ues compared with wild mammalian herbivores, carnivores, 
and omnivores. Convincing data indicate that the “Western” 
atherogenic diet is primarily responsible.610,538
Only a short time ago, the overriding concerns were basi-
cally: could such low LDL-C values be achieved; would it be 
safe to do so; and would sufficient clinical benefits be real-
ized? The current tentative answers appear to be: yes; yes; and 
probably yes. Noting that answers to the last question must rest 
upon logical inference rather than hard evidence,   Forrester255 
cites the .60% decrease in cardiac events associated with a 
lifetime of LDL-C lowering in PCSK-9 hypofunction muta-
tions to argue for prolonged statin therapy, and challenges 
the currently accepted   “normals” for LDL-C levels. Further, 
a single “physiological” or putative normal LDL-C level 
– 50–70 mg/dL – could replace multiple targets presently 
assigned by global risk. Such an approach is supported by 
pathologic, epidemiologic and clinical trial data.233
The evidence that at very low levels of LDL-C cardio-
vascular events may approximate zero comes from several 
venues. First, comparative physiology of mammals and early 
human life indicate a genetic set-point for LDL-C that is 
less than half of the average untreated value in the   Western 
world, ≈3.4 mmol/L (130 mg/dL). Feeding studies in many 
species of mammals vs those in the wild demonstrate a 
dose-related association of the Western diet with athero-
sclerosis. Near absence of atherosclerosis is associated with 
longevity and low LDL-C levels in contemporary hunter-
gatherer societies.610,611 When diets of such individuals are 
westernized, a rise in LDL-C and atherosclerosis progress 
  hand-in-hand.612 Extrapolation of event rates at progressively 
reduced LDL-C levels in primary and secondary prevention 
trials using statins implies that at very low levels, as men-
tioned above, events would virtually be eliminated.608,609
In a meta-analysis conducted by the Cholesterol Treatment 
Trialists’ Collaboration,233 a total of 170,000 high-risk partici-
pants in 26 randomized trials who began with an LDL-C of 
1.8 mmol/L (70 mg/dL), were treated down to ≈1.3 mmol/L 
(50 mg/dL). With each 1 mmol/L reduction, the number 
of occlusive vascular events fell by about 20%, regardless 
of baseline LDL-C. However, despite the suggestion that 
stringent reduction of LDL-C could lower risk by about 
40%–50%, reducing events across the board by 50% in the 
general population, especially with simvastatin, has yet to 
be demonstrated. In a large study of asymptomatic primary 
care patients with LDL-C , 130 mg/dL and CRP $ 2 mg/L, 
those who who attained LDL-C , 50 mg/dL when treated 
with rosuvastatin 20 mg showed a striking 65% fall in the 
risk of cardiovascular events and a 46% reduction in total 
mortality.344 Benefits were not associated with either the 
baseline LDL-C level or with a significant increase in adverse 
events. These data are consistent with the view that very low 
levels of LDL-C , 70 mg/dL may be achieved safely and 
produce greater improvements in outcomes than nonaggres-
sive therapy. When indicated, lower appears to be better.
Setting a goal equal to the “physiologic” LDL-C in 
almost everyone has an immense advantage of simplicity. 
The ease with which this policy could be applied might 
raise adherence by practitioners and patients alike. However, 
this bold proposal is also accompanied by some uncertain-
ties and caveats. Drawbacks related to toxicity, cost, and 
differences in potency may preclude achieving putatively 
physiological LDL-C levels in at least 25% of patients. Risk 
also varies according to variables other than LDL-C levels, 
including HDL-C, other triglyceride rich fractions, non-lipid 
risk factors, inflammation, enzyme activities, etc. Many 
individuals may resist preventive treatment, because they do 
not feel ill, with no discernible immediate physical benefit, 
added inconvenience and cost, and fear of side effects, which 
are widely disseminated on the internet. These factors may 
make adherence poorer than current levels, not better. The 
extent of adherence is probably of greater importance than 
the particular approach used.
It should be emphasized the notion that achieving an 
LDL-C of 50 mg/dL would lower cardiac events to negligible 
levels is theoretical, not proven. For example, many doubt 
that cardiovascular events would be eliminated in diabetics if 
LDL-C levels of 50 mg/dL – values observed in rats, cattle, 
and deer – were achieved. Such a prediction assumes that 
nearly 100% of CHD events may be explained by LDL-C 
elevation above that putative “physiological” value. In addi-
tion, present-day hunter-gatherer individuals experience a 
different life than those in developed civilizations, with a 
sizeable difference in exercise level, stress and pollutant 
exposure. Hence, while more intensive reduction in LDL-C 
will produce significant improvements in reducing cardio-
vascular events, only a partial, rather than total, amelioration 
will likely result from this proposal.
Follow treat-to-target lowering  
of LDL-C, but raise HDL-C
Keeping in mind that just ≈30% of cardiovascular events are 
prevented with statins, and even when maximally tolerated 
doses are used, only a further 16% can be suppressed, Drexel Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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et al613 sought to identify the factors that were responsible for 
the residual risk in non-diabetic and diabetic patients. In a 
small study, vascular events were recorded over 5.6 years in 
491 consecutive statin-treated patients with angiographically-
proven stable CHD, amounting to 2750 patient-years. High 
values of triglycerides, small dense LDL, and low values of 
HDL-C and apoA-I predicted vascular events, but not LDL-C 
or apoB levels. In a small observational study, such results 
were only suggestive, but highlighted the potential impor-
tance of low HDL-C as a predictor of cardiovascular risk, 
especially in statin-treated patients. In a larger (n = 2910), 
community-based sample in the Framingham Heart Study, 
additional CHD risk associated with high TG or low HDL-C 
levels was only found in patients with insulin resistance.630
There has been considerable progress in understanding 
HDL metabolism, and interest in raising HDL-C levels as a 
means of reducing risk is keen. Larger ongoing clinical trials 
that target specific pathways in HDL metabolism may provide 
sufficiently robust data to support new treatment options. The 
present investigative focus includes increasing HDL-mediated 
reverse cholesterol transport, raising the proportion of more 
effective HDL subfractions, or producing functioning human 
apoA-I or surrogate molecules. Generally, there is only mod-
est evidence showing that raising HDL-C, in addition to what 
is achieved by lifestyle modification alone, will improve 
outcomes.358 Both the European31 and   Canadian190 guidelines 
for dyslipidemia management emphasize that trial data do 
not show pharmacological treatment of HDL-C will lower 
cardiovascular risk. Indeed, recent reports using fibrates and 
niacin to lower risk have not changed this view.
Use a modified traditional approach 
which preserves LDL-C targets
Nambi and Ballantyne227 proposed a formal protocol using the 
FRS, lifetime risk, and CRP, CIMT, CAC or genetic risk mark-
ers for further progressive refinement of stratification. After 
initially estimating FRS, if risk was .20%, the LDL-C goal 
would be 70 mg/dL. If FRS was low, or 0%–10%, lifetime 
risk would then be determined. For individuals with both a 
low 10-year and low lifetime risk, the prevailing NCEP-ATP 
protocol would apply. For those with a low 10-year risk, but 
a high lifetime risk, further stratification using CRP, CIMT, 
CAC score or genetic risk markers would be undertaken.
Finally, for those with an FRS of 10%–20% at intermediate 
risk, the current ATP III guidelines advise an LDL-C goal 
of ,130 mg/dL and an optional goal of ,100 mg/dL, which 
may change in ATP IV guidelines. These investigators also 
agree that the LDL-C value at birth, ≈50 mg/dL, may be 
physiological, and cardiovascular benefits would be expected 
until those values are reached.
Give statins to low- and intermediate-risk 
individuals within a polypill
The polypill concept was proposed by Wald and Law614 
to lower LDL-C, blood pressure, serum homocysteine, 
and inhibit platelets regardless of pretreatment levels in a 
large segment of the population (over age 55), produce few 
side effects, with minimal expense. As safety of treatment 
rises and expense falls, risk stratification is considered less 
 valuable. One-third of people taking this pill from age 55 
were expected to benefit, adding an average of 11 years to 
life, free from a CHD event or stroke.614
In the Indian Polycap Study (TIPS), a polycap containing 
low doses of thiazide (12⋅5 mg), atenolol (50 mg), ramipril 
(5 mg), simvastatin (20 mg), and aspirin (100 mg) was studied 
in 2053 Indian subjects without cardiovascular disease, but 
with at least 1 risk factor613 Based upon the results, there was 
a potential for a 62% reduction in relative risk in CHD and a 
48% lowering of relative risk for stroke. This was short of the 
80% risk reduction originally envisioned.614,616 Not surprisingly, 
even though well-tolerated, acceptance and adherence was still 
a significant problem. A polypill feasibility study in Sri Lanka 
sponsored by WHO617 found high patient acceptability, which 
need not have correlation with future adherence or outcomes. 
Compared to other techniques, the use of a polypill does not 
depend heavily upon personal responsibility for lifestyle 
change, since instructions are simple. Unfortunately, adher-
ence to poor diets and inactivity is greater than adherence to 
polypills, and the protection afforded by the polypill, although 
impressive and with many advantages,618–620 remains incom-
plete. Although it will go a long way in reducing cardiovascular 
risk, final long-term success in hard end points remains to be 
seen. The Use of a Multidrug Pill In Reducing cardiovascular 
Events (UMPIRE) study is beginning in the UK and in other 
venues, while other studies sponsored by WHO are in prog-
ress. In populated poor countries, the polypill may ultimately 
provide better protection than expensive, sophisticated care.
Conclusion
Alternatives for improving cardiovascular prevention based 
upon evolving concepts, new data, and revised goals have 
changed remarkably in recent years. In primary prevention, 
traditional risk factors used in combination to generate global 
scores do not predict risk well enough, nor do they discriminate 
sufficiently between those who will have cardiovascular events 
and those who will not. Chosing the best mix of approaches for Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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cardiovascular prevention cannot presently be based upon hard 
end point data, but partially upon an evidence-based synthesis 
using inductive reasoning. Even though the original belief that 
prevention was cost-ineffective has now been disproven,621 at 
least for cardiovascular applications, there has been disappoint-
ing progress in effecting successful population-based primordial 
prevention. For truly effective improvements in cardiovascular 
risk, primordial prevention appears necessary as an adjunct to 
the high-risk strategy traditionally offered to individual patients. 
Wilkins and Lloyd-Jones526 explicitly declare that the present 
paradigm of identifying high-risk individuals alone will never 
succeed in lowering the risk burden, even without considering 
further progression of obesity and diabetes.
The magnitude of the problem – pervasive poor car-
diovascular health and its importance – has not been fully 
appreciated. Psychosocial aspects of behavior in embracing 
and adhering to primordial, primary, and secondary prevention 
are receiving greater attention.85–87,622–626 According to one 
health belief model, negative health behavior is in part 
due to the widespread failure of people to accept disease 
preventives when disease is asymptomatic.627 Part of the 
complex belief system involved leads to unrealistic optimism 
of vulnerability.628 During assessment, the psychology and 
inaccuracy of patient perceptions of risk and the factors 
leading to physicians’ underestimation of patients’ risk are 
significant and incompletely understood.170–173,198 As far as 
the estimation of cardiovascular risk burden is concerned, 
the chasm between perception and reality persists for both 
physicians and patients in North America, UK, and the EU. 
Given the lack of success and resistance to primordial 
prevention, population-wide pharmacological reduction of 
risk, previously rejected because of expense and potential side 
effects, is being reevaluated as a cost-effective   maneuver. If 
one restricts evidence-based cardiovascular risk reduction to 
statins, the question reduces to what segment of the population 
will be eligible for how much of what statin or polypill.
Recent evidence suggests that attention to pediatric 
patients, at a time when habits are formed, and monitoring 
of adolescents as well as young adults, must increase.
The 2010 ACCF/AHA Guideline for Assessment of 
Cardiovascular Risk in Asymptomatic Adults,32 a con-
sensus of experts, reaffirmed a central role for global risk 
scoring in assessing risk in all adults. Similarly, a family 
history was recommended for all patients. While recogniz-
ing the large risk burden in asymptomatic adults, difficulty 
in identification of patients who ultimately suffer cardio-
vascular events, the significant number of patients who 
remain untreated and eventually succumb to CHD deaths, 
this guideline set forth evidence-based recommendations 
for the identification and stratification of patients at risk.
Use of the Reynolds Risk Score, particularly in women, 
deserves consideration.629 Lowering the threshold for risk 
level may bring more care to patients who will benefit. In the 
2011 American Heart Association update to the guidelines for 
prevention of cardiovascular disease in women,629 “high risk” 
among women is now defined as a 10-year CVD risk $ 10% 
rather than $20%.
Of all biomarkers, CRP is the best studied circulat-
ing biomarker, and provides information about activation 
of upstream cytokines driving inflammation. High levels 
of CRP are associated with endothelial dysfunction and 
predict future cardiovascular events. Use of C-reactive 
protein is recommended or accepted in guidelines for 
specific patients with intermediate risk.15 Among imaging 
techniques, CIMT reflects intima-media thickening due 
to progression of atherosclerosis, refines risk assessment 
beyond global risk scores, improves predictability, and 
has been used successfully for serial re-evaluations. CAC 
documents the extent of calcification, a process which occurs 
later in the evolution of atherosclerosis. Patients with higher 
CAC scores generally have advanced, diffuse disease with 
  accompanying noncalcified vulnerable lesions, accounting 
for its high prognostic value. Increasing appropriate use of 
CAC and CIMT, according to clinical circumstances, will 
refine risk evaluation, help guide treatment, and probably 
improve outcomes. Use of both CRP and CAC, since infor-
mation provided involve orthogonal mechanisms, may offer 
unique advantages.631,632 Recent work suggests that elevations 
in CRP levels predict a higher burden of coronary plaque, 
particularly mixed calcified arterial plaque, in asymptomatic 
individuals.634 Rises in CRP concentrations appear to be asso-
ciated with vulnerable plaque, drawing still more attention to 
the important role of inflammation in atherosclerosis.635
In patients with high risk, aggressive treatment to reduce 
risk factors should be instituted early and maintained for 
years. Since the incubation period and signs and symptoms 
of atherosclerosis span decades, randomized trials of a few 
years’ duration provide little insight into outcomes of statin 
treatment over those 40–60 years. The most aggressive 
stance would include immediate treatment of patients with 
high- (FRS $ 20% or equivalent) or even intermediate-risk 
(FRS 10%–20%) with high potency statins. Rosuvastatin 
and high dose atorvastatin are drugs of choice, even if the 
baseline LDL-C is not elevated. Rosuvastatin produces the 
greatest reduction in LDL-C, LDL-P, and improvement in 
apoA-I/apoB with a favorable safety profile. Lowering current Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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LDL-C goals will undoubtedly enhance risk control and 
reduce event rates. However, even if all such patients received 
statins, cardiovascular events would still continue. The search 
for additional methods to lower residual risk, including using 
non-HDL-C as a target, raising functional HDL-C levels,636 
and mining LDL-C subfractions for clinically useful informa-
tion, continues. The recent negative trials using torcetrapib, 
fibrates, and extended-release niacin are significant and col-
lectively discouraging. This is particularly true concerning 
niacin in AIM-HIGH, in view of prior evidence supporting 
the use of this drug in a meta-analysis of 14 smaller trials637 
and ARBITER 6-HALTS. Nevertheless, the data reinforce 
the theme of this paper: intensive, unrelenting, lifestyle 
improvement and aggressive statin therapy are two pillars of 
management in the prevention of cardiovascular disease. 
The enormity of pervasive poor cardiovascular health 
and its importance have not been fully appreciated and 
valued by the public, the media, health policy authorities, 
or legislators. Barring major unpalatable political changes, 
current trends in cardiovascular risk will undoubtedly con-
tinue. As such, there will be an even greater demand for 
pharmacological and invasive therapies. Most likely, success 
will be achieved through a combination of ongoing improve-
ments in adherence, guideline compliance, novel treatments, 
and the valuable addition of primordial prevention in the 
form of programs such as the American Heart Association’s 
Life’s Simple 7TM. Cooperation is essential, and each one of 
us – citizens, patients, biochemists, physicians, researchers, 
administrators, and public officials – have an essential role in 
supporting this common goal. Obstacles will be many, and the 
road hard and long, but recent advances now offer us greater 
and unique opportunities to meet the imposing challenge.
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